[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 15068
1. Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ, UK Dermatology Clinical Trials Network BLISTER Study Group: Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet; 2017 Apr 22;389(10079):1630-1638
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bullous pemphigoid is a blistering skin disorder with increased mortality.
  • We tested whether a strategy of starting treatment with doxycycline gives acceptable short-term blister control while conferring long-term safety advantages over starting treatment with oral corticosteroids.
  • The primary safety outcome was the proportion with severe, life-threatening, or fatal (grade 3-5) treatment-related adverse events by 52 weeks.
  • Analysis (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol for non-inferiority effectiveness analysis) used a regression model adjusting for baseline disease severity, age, and Karnofsky score, with missing data imputed.
  • FUNDING: NIHR Health Technology Assessment Programme.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.
  • [Cites] Lancet. 2013 Jan 26;381(9863):320-32 [23237497.001]
  • [Cites] Vet Hum Toxicol. 1988 Oct;30(5):431-43 [3055652.001]
  • [Cites] Singapore Med J. 2000 Jul;41(7):327-30 [11026799.001]
  • [Cites] Clin Exp Dermatol. 2013 Apr;38(3):311-3 [23517364.001]
  • [Cites] J Invest Dermatol. 2015 May;135(5):1445-7 [25560279.001]
  • [Cites] Stat Med. 2003 Jan 30;22(2):169-86 [12520555.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):17-8 [26174646.001]
  • [Cites] J Am Acad Dermatol. 2014 Dec;71(6):1191-7 [25174542.001]
  • [Cites] Medicine (Baltimore). 1953 Feb;32(1):1-123 [13024494.001]
  • [Cites] JAMA Dermatol. 2013 Jan;149(1):58-62 [23324757.001]
  • [Cites] J Invest Dermatol. 2012 Aug;132(8):1998-2004 [22418872.001]
  • [Cites] Arch Dermatol. 2010 Nov;146(11):1251-4 [21079062.001]
  • [Cites] Health Technol Assess. 2017 Mar;21(10 ):1-90 [28406394.001]
  • [Cites] J Am Acad Dermatol. 2012 Mar;66(3):479-85 [22056920.001]
  • [Cites] Br J Dermatol. 2015 Jul;173(1):227-34 [25683592.001]
  • [Cites] N Engl J Med. 2002 Jan 31;346(5):321-7 [11821508.001]
  • [Cites] Lancet. 1984 Sep 1;2(8401):486-8 [6147549.001]
  • [Cites] Clin Exp Dermatol. 2016 Jul;41(5):506-9 [26940484.001]
  • [Cites] BMJ. 2008 Jul 09;337:a180 [18614511.001]
  • [Cites] J Invest Dermatol. 2009 Jul;129(7):1681-7 [19177141.001]
  • [Cites] Br J Dermatol. 2015 Apr;172(4):867-77 [25827742.001]
  • [Cites] Trials. 2012 Apr 27;13:50 [22540678.001]
  • [Cites] Br J Dermatol. 2012 Dec;167(6):1200-14 [23121204.001]
  • [Cites] Br J Dermatol. 2016 Apr;174(4):919-21 [26556709.001]
  • [Cites] Cochrane Database Syst Rev. 2010 Oct 06;(10):CD002292 [20927731.001]
  • [Cites] J Invest Dermatol. 2011 Mar;131(3):637-43 [20944650.001]
  • [Cites] Br J Dermatol. 1979 Nov;101(5):521-34 [391261.001]
  • [Cites] Arch Dermatol. 1994 Jun;130(6):753-8 [8002646.001]
  • [Cites] Pharmacol Res. 2011 Feb;63(2):130-45 [20937386.001]
  • (PMID = 28279484.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Adams J; Akhras V; Anstey A; Barnard C; Bell H; Blackford S; Bröcker E; Carmichael A; Coelho RR; Craig F; Davies K; Ellis R; English J; Gläser R; Groves R; Günthert C; Hampton PJ; Hepburn N; Hügel R; Hussain K; Ingram J; Layton AM; Levell NJ; Lewis V; Malhomme H; Omerod A; Patel G; Rallan R; Ravenscroft J; Santander H; Steinbrink K; Sticherling M; Thomas C; Vatve M; van Beek N; Venning V; Veysey E; Wachsmuth R; Wahie S; Walker B; Walsh M; Wee J; Westmoreland M; Wong G; Ferguson A; Verpetinske I; Duarte-Williamson E; Antony F; Bower C; Gawkrodger D; Taghipour K; Dunnill MGS; Waters A; Bottomley W; Wright A; Sterling J; Azam A; Gibbs S; Luger T; Salvary I; Lovell C; Ilchyshyn A; Gibbon K; Nik M; Charles-Holmes R; Lavery AL
  •  go-up   go-down


2. Puschner B, Bautista AC, Wong C: Debromoaplysiatoxin as the Causative Agent of Dermatitis in a Dog after Exposure to Freshwater in California. Front Vet Sci; 2017;4:50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although cases of acute hepato- and neurotoxicoses in dogs following cyanotoxin exposure exist, no reports of skin-related reactions in dogs exist.
  • Assessment of the dog's environment revealed access to a lake on the property with visible algal bloom.
  • Access to the lake was discontinued and follow-up evaluation over the next few weeks revealed a complete resolution of the skin irritation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicon. 2008 Aug 1;52(2):385-8 [18585400.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):554-62 [17585335.001]
  • [Cites] J Vet Emerg Crit Care (San Antonio). 2010 Oct;20(5):518-22 [20955303.001]
  • [Cites] J Am Anim Hosp Assoc. 2013 Sep-Oct;49(5):342-6 [23861261.001]
  • [Cites] Hawaii Med J. 1959 Sep-Oct;19:32-4 [13829055.001]
  • [Cites] Arch Dermatol. 1978 Sep;114(9):1333-5 [686747.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 1995 Oct 6;44(39):724-7 [7565550.001]
  • [Cites] Toxicon. 2005 Jun 1;45(7):919-28 [15904687.001]
  • [Cites] BMC Dermatol. 2008 Dec 30;8:5 [19116031.001]
  • [Cites] J Am Chem Soc. 1974 Apr 3;96(7):2245-6 [4833645.001]
  • [Cites] Toxicon. 2012 Nov;60(6):1148-58 [22960450.001]
  • [Cites] BMC Public Health. 2006 Apr 11;6:93 [16606468.001]
  • [Cites] Hawaii Med J. 1982 Jul;41(7):200-1 [7129866.001]
  • [Cites] Arch Dermatol. 1961 Nov;84:720-32 [13901248.001]
  • [Cites] Harmful Algae. 2016 Apr;54:213-222 [28073478.001]
  • [Cites] J Immunol. 2003 Sep 1;171(5):2703-13 [12928424.001]
  • [Cites] Toxicon. 1996 Jul;34(7):753-61 [8843576.001]
  • [Cites] Chemosphere. 2014 Feb;96:1-15 [24012139.001]
  • [Cites] Mol Nutr Food Res. 2007 Jan;51(1):7-60 [17195276.001]
  • [Cites] J Vet Diagn Invest. 2008 Jan;20(1):89-92 [18182518.001]
  • [Cites] Int J Dermatol. 2012 Jan;51(1):59-62 [21790555.001]
  • [Cites] Science. 1977 Apr 29;196(4289):538-40 [403608.001]
  • [Cites] J Vet Diagn Invest. 1993 Jul;5(3):403-8 [8373855.001]
  • [Cites] Environ Int. 2013 Sep;59:303-27 [23892224.001]
  • [Cites] Environ Toxicol. 2001;16(6):512-6 [11769249.001]
  • [Cites] Sci Total Environ. 2014 Jan 1;466-467:397-403 [23927933.001]
  • [Cites] Environ Health Perspect. 2016 Apr;124(4):477-83 [26383636.001]
  • [Cites] Science. 1983 Dec 16;222(4629):1242-4 [6316505.001]
  • [Cites] Mar Drugs. 2016 Mar 09;14 (3):null [27005635.001]
  • [Cites] Toxicon. 1998 Dec;36(12):1913-20 [9839675.001]
  • [Cites] BMC Vet Res. 2015 Jun 19;11:136 [26087767.001]
  • [Cites] Cancer Res. 1983 Oct;43(10):4676-80 [6883326.001]
  • (PMID = 28428958.001).
  • [Journal-full-title] Frontiers in veterinary science
  • [ISO-abbreviation] Front Vet Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Lyngbya sp. / cyanobacteria / cyanotoxins / debromoaplysiatoxin / dog / skin irritation / toxicosis
  •  go-up   go-down


3. Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N: Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. Drug Saf; 2017 Apr;40(4):317-331

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
  • METHODS: A retrospective analysis of public Facebook and Twitter data was conducted for 10 recent FDA postmarketing safety signals at the drug-event pair level with six negative controls.
  • Drug safety physicians conducted a manual review to determine causality using World Health Organization-Uppsala Monitoring Centre (WHO-UMC) assessment criteria.
  • Of these, 13 posts were selected for causality assessment of product-event pairs.
  • Clinical assessment revealed that posts had sufficient information to warrant further investigation for two possible product-event associations: dronedarone-vasculitis and Banana Boat Sunscreen--skin burns.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Drug Saf. 2015;14(12):1845-53 [26436834.001]
  • [Cites] J Biomed Inform. 2015 Jun;55:73-81 [25817970.001]
  • [Cites] Patient Prefer Adherence. 2015 Jan 23;9:173-84 [25670886.001]
  • [Cites] Drug Saf. 2014 Oct;37(10):761-4 [25096955.001]
  • [Cites] J Med Internet Res. 2015 Jul 10;17(7):e171 [26163365.001]
  • [Cites] J Biomed Inform. 2016 Feb;59:42-8 [26610385.001]
  • [Cites] Nat Rev Rheumatol. 2015 Feb;11(2):119-23 [25314016.001]
  • [Cites] J Biomed Inform. 2011 Dec;44(6):989-96 [21820083.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1161-6 [17486665.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2013 Mar;22(3):256-62 [23322591.001]
  • [Cites] J Am Board Fam Pract. 2004 Mar-Apr;17(2):142-9 [15082674.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:202-12 [25720841.001]
  • [Cites] J Clin Pharm Ther. 2014 Feb;39(1):53-5 [24304185.001]
  • [Cites] Drug Saf. 2011 Apr 1;34(4):267-71 [21417499.001]
  • [Cites] Methods Inf Med. 2013;52(2):152-9 [23450374.001]
  • [Cites] Drug Saf. 2016 May;39(5):443-54 [26798054.001]
  • [Cites] Eur J Clin Pharmacol. 2013 Feb;69(2):209-15 [22688722.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):239-46 [24713590.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):910-20 [26147850.001]
  • [Cites] Drug Saf. 2014 Aug;37(8):629-37 [25027671.001]
  • [Cites] Adv Psychobiol. 1974;2:297-312 [4476178.001]
  • [Cites] N Z Med J. 2014 Aug 29;127(1401):69-81 [25225758.001]
  • [Cites] Drug Saf. 2014 May;37(5):343-50 [24777653.001]
  • [Cites] J Biomed Inform. 2015 Feb;53:196-207 [25451103.001]
  • [Cites] J Med Internet Res. 2007 Feb 28;9(1):e4 [17478413.001]
  • [Cites] J Med Internet Res. 2011 May 17;13(2):e37 [21586386.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2153-5, 2157 [19423867.001]
  • [Cites] J Addict Dis. 2015;34(4):303-10 [26364675.001]
  • [Cites] Br J Clin Pharmacol. 1996 Oct;42(4):423-9 [8904613.001]
  • [Cites] Br J Clin Pharmacol. 2015 Oct;80(4):878-88 [26271492.001]
  • [Cites] J Biomed Inform. 2015 Apr;54:230-40 [25688695.001]
  • [Cites] J Am Med Inform Assoc. 2015 May;22(3):671-81 [25755127.001]
  • [Cites] Drug Saf. 1999 Feb;20(2):95-107 [10082068.001]
  • [Cites] Clin Pharmacol Ther. 2014 Aug;96(2):149-50 [25056395.001]
  • [Cites] Drug Saf. 2015 Oct;38(10):921-30 [26242616.001]
  • [Cites] Res Social Adm Pharm. 2014 Nov-Dec;10(6):896-903 [24603135.001]
  • [Cites] Trends Pharmacol Sci. 2013 Jul;34(7):357-8 [23759353.001]
  • [Cites] J Antimicrob Chemother. 2014 Sep;69(9):2568-72 [24862092.001]
  • [Cites] AMIA Annu Symp Proc. 2014 Nov 14;2014:924-33 [25954400.001]
  • [Cites] J Nerv Ment Dis. 1972 Nov;155(5):363-5 [5082173.001]
  • (PMID = 28044249.001).
  • [ISSN] 1179-1942
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


Advertisement
4. Nam CH, Park BC, Kim MH, Choi EH, Hong SP: The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles. Dermatol Surg; 2017 Feb 09;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of 660 nm and 411 to 777 nm Light-Emitting Devices for Treating Wrinkles.
  • BACKGROUND: Low-level light therapy (LLLT) using light-emitting diodes (LEDs) is considered to be helpful for skin regeneration and anti-inflammation.
  • OBJECTIVE: To evaluate the efficacy and safety of 2 types of LLLTs using 660 nm-emitting red LEDs and 411 to 777 nm-emitting white LEDs in the treatment of facial wrinkles.
  • RESULTS: In both groups treated with red and white LEDs, the wrinkle measurement from skin replica improved significantly from baseline at Week 12.
  • In the global assessment of the subjects, the mean improvement score of the red LED group was higher than that of the white LED group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28195844.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Omland SH, Habicht A, Damsbo P, Wilms J, Johansen B, Gniadecki R: A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis. J Eur Acad Dermatol Venereol; 2017 Jan 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, double-blind, placebo-controlled, dose-escalation first-in-man study (phase 0) to assess the safety and efficacy of topical cytosolic phospholipase A2 inhibitor, AVX001, in patients with mild to moderate plaque psoriasis.
  • BACKGROUND: Cytosolic phospholipase A2 (cPLA2α) is an enzyme suggested as a therapeutic target in inflammatory skin diseases.
  • OBJECTIVES: The primary objective was to evaluate cutaneous safety and tolerability of AVX001 in doses from 0.002% to 5.0%.
  • Safety was assessed as local skin reaction adverse events (LSRAE) grades 3-4.
  • The secondary objective was assessment of efficacy on modified PASI (mPASI) score compared with placebo.
  • The treatment period was four weeks with two-week follow-up with assessment at screening, randomization and once weekly until study end.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107559.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA: Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics. Int J Toxicol; 2017 May/Jun;36(1_suppl):17S-56S

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety Assessment of Amino Acid Alkyl Amides as Used in Cosmetics.
  • The Cosmetic Ingredient Review Expert Panel (Panel) reviewed the product use, formulation, and safety data of 115 amino acid alkyl amides, which function as skin and hair conditioning agents and as surfactants-cleansing agents in personal care products.
  • Safety test data on dermal irritation and sensitization for the ingredients with the highest use concentrations, lauroyl lysine and sodium lauroyl glutamate, were reviewed and determined to adequately support the safe use of the ingredients in this report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28553738.001).
  • [ISSN] 1092-874X
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; amino acid alkyl amides / cosmetics / safety
  •  go-up   go-down


7. Wittwehr C, Aladjov H, Ankley G, Byrne HJ, de Knecht J, Heinzle E, Klambauer G, Landesmann B, Luijten M, MacKay C, Maxwell G, Meek ME, Paini A, Perkins E, Sobanski T, Villeneuve D, Waters KM, Whelan M: How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology. Toxicol Sci; 2017 Feb;155(2):326-336

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efforts are underway to transform regulatory toxicology and chemical safety assessment from a largely empirical science based on direct observation of apical toxicity outcomes in whole organism toxicity tests to a predictive one in which outcomes and risk are inferred from accumulated mechanistic understanding.
  • We argue that the systematic organization of knowledge into AOP frameworks can inform and help direct the design and development of computational prediction models that can further enhance the utility of mechanistic and in silico data for chemical safety assessment.
  • Examples of AOP-informed model development and its application to the assessment of chemicals for skin sensitization and multiple modes of endocrine disruption are provided.
  • The role of problem formulation, not only as a critical phase of risk assessment, but also as guide for both AOP and complementary model development is described.
  • The contents serve as a vision for how AOPs can be leveraged to facilitate development of computational prediction models needed to support the next generation of chemical safety assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Society of Toxicology.
  • [Cites] Toxicol Sci. 2013 Mar;132(1):75-86 [23288054.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1333-47 [25824844.001]
  • [Cites] Environ Toxicol Chem. 2015 Jul;34(7):1623-33 [25943079.001]
  • [Cites] Toxicology. 2012 Jan 27;291(1-3):18-24 [22120538.001]
  • [Cites] Environ Toxicol Chem. 2010 Mar;29(3):730-41 [20821501.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1875-87 [26360911.001]
  • [Cites] PLoS One. 2013 May 30;8(5):e63308 [23737943.001]
  • [Cites] Environ Health Perspect. 2016 May;124(5):556-62 [26431337.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2010 Feb;13(2-4):51-138 [20574894.001]
  • [Cites] Bioinformatics. 2012 May 1;28(9):1193-201 [22423044.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Toxicol Sci. 2015 Feb;143(2):319-32 [25338925.001]
  • [Cites] Environ Health Perspect. 2013 Sep;121(9):1002-10 [23771518.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2016 May-Jun;183-184:36-45 [26875912.001]
  • [Cites] Regul Toxicol Pharmacol. 2010 Dec;58(3):369-81 [20801182.001]
  • [Cites] Ann N Y Acad Sci. 2007 Dec;1115:1-22 [17925349.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Toxicol Sci. 2013 Jun;133(2):234-47 [23475784.001]
  • [Cites] Environ Res. 2012 Aug;117:90-9 [22770859.001]
  • [Cites] Environ Toxicol Chem. 2011 Feb;30(2):265-73 [21072840.001]
  • [Cites] BMC Syst Biol. 2011 May 05;5:63 [21545743.001]
  • [Cites] Int J Androl. 2008 Apr;31(2):209-23 [18217984.001]
  • [Cites] Mutat Res. 2009 Mar-Jun;681(2-3):230-40 [19010444.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):14-25 [26500288.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Toxicol In Vitro. 2014 Feb;28(1):8-12 [24184331.001]
  • [Cites] Environ Sci Technol. 2016 May 3;50(9):4579-86 [26759916.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):471-83 [25236459.001]
  • [Cites] Environ Sci Technol. 2015 Jul 21;49(14):8804-14 [26066997.001]
  • [Cites] Toxicol In Vitro. 2015 Feb;29(1):259-70 [25448812.001]
  • [Cites] Regul Toxicol Pharmacol. 2013 Jun;66(1):116-29 [23535119.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Feb;11(2):259-71 [25440524.001]
  • [Cites] Nat Biotechnol. 2011 Sep 08;29(9):811-5 [21904331.001]
  • [Cites] Front Pharmacol. 2015 May 27;6:107 [26074819.001]
  • [Cites] Ecotoxicol Environ Saf. 2004 Sep;59(1):1-9 [15261716.001]
  • [Cites] Toxicol Sci. 2011 Dec;124(2):432-45 [21964421.001]
  • [Cites] Toxicol Sci. 2011 Feb;119(2):308-18 [20966114.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Aug;72(3):514-37 [25863193.001]
  • [Cites] Toxicol Sci. 2014 Dec;142(2):312-20 [25466378.001]
  • [Cites] Regul Toxicol Pharmacol. 2015 Apr;71(3):463-77 [25707856.001]
  • [Cites] Environ Health Perspect. 2014 Dec;122(12):1261-70 [25117432.001]
  • [Cites] Environ Res. 2012 Jul;116:74-84 [22575326.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Nat Biotechnol. 2015 Sep;33(9):933-40 [26258538.001]
  • [Cites] Chem Res Toxicol. 2012 Jul 16;25(7):1287-302 [22519603.001]
  • [Cites] Toxicology. 2015 Jun 5;332:112-23 [25598226.001]
  • [Cites] Environ Mol Mutagen. 2015 Jul;56(6):520-34 [25733247.001]
  • [Cites] Toxicol Sci. 2015 Nov;148(1):137-54 [26272952.001]
  • [Cites] J Appl Toxicol. 2013 Nov;33(11):1353-64 [23670904.001]
  • [Cites] Altern Lab Anim. 2007 Mar;35(1):25-32 [17411348.001]
  • [Cites] PLoS One. 2016 Jan 12;11(1):e0146594 [26756814.001]
  • [Cites] ALTEX. 2013;30(4):473-86 [24173169.001]
  • [Cites] J Appl Toxicol. 2015 Nov;35(11):1318-32 [25820183.001]
  • [Cites] Bioinformatics. 2015 Feb 15;31(4):453-61 [24994890.001]
  • (PMID = 27994170.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P42 ES016465
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; AOP / Adverse Outcome Pathways / computational prediction model. / quantitative AOP
  •  go-up   go-down


8. Bhattacharyya A, Jain N, Prasad S, Jain S, Yadav V, Ghosh S, Sengupta S: Evaluation of therapeutic potential of VB-001, a leave-on formulation, for the treatment of moderate adherent dandruff. BMC Dermatol; 2017 May 03;17(1):5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine the efficacy and skin safety of VB-001 antidandruff leave-on formulation in comparison with marketed antidandruff ZPTO shampoo in patients with moderate adherent dandruff of the scalp.
  • The efficacy of each product was evaluated by comparing proportion of subjects who have shown reduction in flaking by ASFS (adherent scalp flaking score) and pruritus by IGA (investigator global assessment) score.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 1975 Jun;64(6):401-5 [237965.001]
  • [Cites] J Clin Aesthet Dermatol. 2011 Sep;4(9):22-42 [21938268.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):194-7 [16382662.001]
  • [Cites] J Investig Dermatol Symp Proc. 2005 Dec;10(3):295-7 [16382685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18730-5 [18000048.001]
  • [Cites] Int J Cosmet Sci. 2006 Oct;28(5):311-8 [18489295.001]
  • [Cites] Br J Dermatol. 1984 Aug;111(2):235-42 [6235835.001]
  • [Cites] Indian J Dermatol. 2010 Apr-Jun;55(2):130-4 [20606879.001]
  • [Cites] Int J Cosmet Sci. 2012 Aug;34(4):298-306 [22515370.001]
  • [Cites] J Cosmet Dermatol. 2010 Sep;9(3):202-10 [20883293.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6):897-903 [11712036.001]
  • [Cites] Contact Dermatitis. 2002 Jan;46(1):6-12 [11918580.001]
  • [Cites] Mycoses. 2015 Apr;58(4):215-9 [25676074.001]
  • [Cites] Crit Care Med. 1999 Sep;27(9):1781-6 [10507598.001]
  • [Cites] Arch Dermatol Res. 2002 Jul;294(5):221-30 [12115025.001]
  • (PMID = 28468620.001).
  • [ISSN] 1471-5945
  • [Journal-full-title] BMC dermatology
  • [ISO-abbreviation] BMC Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Anti-fungals / Dandruff / Malassezia / Scalp
  •  go-up   go-down


9. Meng D, Guo M, Qian Y, Han G: Occurrence and dietary exposure assessment of PFOS and PFOA in cultured Trachinotus ovatus in China. J Environ Sci Health B; 2017 Jul 05;:1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence and dietary exposure assessment of PFOS and PFOA in cultured Trachinotus ovatus in China.
  • The tissue distribution (muscle, skin, liver, kidney and gill) in Trachinotus ovatus was also assessed.
  • The analysis of PFOS distribution in different tissues in Trachinotus ovatus showed the following trend: skin> gill> kidney> liver> flesh.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28679074.001).
  • [ISSN] 1532-4109
  • [Journal-full-title] Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes
  • [ISO-abbreviation] J Environ Sci Health B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Perfluorooctane sulfonate(PFOS) / Trachinotus ovatus / average daily intake / concentration / perfluorooctanoic acid(PFOA) / tissue distribution
  •  go-up   go-down


10. Mahler V, Aalto-Korte K, Alfonso JH, Bakker JG, Bauer A, Bensefa-Colas L, Boman A, Bourke J, Bubaš M, Bulat P, Chaloupka J, Constandt L, Danielsen TE, Darlenski R, Dugonik A, Ettler K, Gimenez-Arnau A, Gonçalo M, Johansen JD, John SM, Kiec-Swierczynska M, Koch P, Kohánka V, Krecisz B, Larese Filon F, Ljubojević S, Macan J, Marinović B, Matura M, Mihatsch PW, Mijakoski D, Minov J, Pace J, Pesonen M, Ramada Rodilla JM, Rast H, Reljic V, Salavastru C, Schuster C, Schuttelaar ML, Simon D, Spiewak R, Jurakic Tončić R, Urbanček S, Valiukevičienė S, Weinert P, Wilkinson M, Uter W: Occupational skin diseases: actual state analysis of patient management pathways in 28 European countries. J Eur Acad Dermatol Venereol; 2017 Jun;31 Suppl 4:12-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational skin diseases: actual state analysis of patient management pathways in 28 European countries.
  • BACKGROUND: Work-related skin diseases (WSD) are caused or worsened by a professional activity.
  • Occupational skin diseases (OSD) need to fulfil additional legal criteria which differ from country to country.
  • OSD range amongst the five most frequently notified occupational diseases (musculoskeletal diseases, neurologic diseases, lung diseases, diseases of the sensory organs, skin diseases) in Europe.
  • OBJECTIVE: To retrieve information and compare the current state of national frameworks and pathways to manage patients with occupational skin disease with regard to prevention, diagnosis, treatment and rehabilitation in different European countries.
  • Legal standards for the assessment of occupationally triggered diseases with a genetic background differ between different countries, however, in most European member states recognition as OSD is possible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28656731.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Jacques-Jamin C, Jeanjean-Miquel C, Domergue A, Bessou-Touya S, Duplan H: Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis. Skin Pharmacol Physiol; 2017;30(2):55-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardization of an in vitro Model for Evaluating the Bioavailability of Topically Applied Compounds on Damaged Skin: Application to Sunscreen Analysis.
  • BACKGROUND: Information is lacking on the dermal penetration of topically applied formulations on in vitro skin models, under conditions where the stratum corneum (SC) is damaged.
  • Therefore, we have developed a standardized in vitro barrier-disrupted skin model using tape stripping.
  • RESULTS: The effects of tape stripping were comparable using pig and human skin.
  • The bioavailability of the filters was extremely low regardless of the extent of skin damage, suggesting bioavailability would not be increased if the consumer applied the sunscreen to sun-damaged skin.
  • CONCLUSION: This standardized in vitro methodology using pig or human skin for damaged skin will add valuable information for the safety assessment of topically applied products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 S. Karger AG, Basel.
  • (PMID = 28278501.001).
  • [ISSN] 1660-5535
  • [Journal-full-title] Skin pharmacology and physiology
  • [ISO-abbreviation] Skin Pharmacol Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Barrier-disrupted skin model / Bioavailability / Human / Pig / Standardized model / Sunscreen filters / Tape stripping
  •  go-up   go-down


12. Bitzer J, Römer T, Lopes da Silva Filho A: The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review. Eur J Contracept Reprod Health Care; 2017 Jun;22(3):172-182
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of cyproterone acetate/ethinyl estradiol in hyperandrogenic skin symptoms - a review.
  • Hyperandrogenic skin symptoms such as hirsutism, acne, seborrhea and alopecia are associated with significant quality of life and psychological impairment.
  • OBJECTIVE: To review the data on the efficacy and safety of CPA 2 mg/EE 35 μg for the treatment of hyperandrogenic skin symptoms in women.
  • Studies show that therapeutic response in women with hirsutism requires a long-term approach and that hyperandrogenic skin symptoms in patients with PCOS are efficiently treated.
  • Safety and tolerability data are summarized by the pharmacovigilance risk assessment committee (PRAC) of the European Medicine's Agency's (EMA).
  • CONCLUSIONS: This review provides a comprehensive overview about the efficacy of CPA 2 mg/EE 35 μg in the treatment of hyperandrogenic skin symptoms, thus allowing both health care professionals and women to balance the risks and benefits of treatment based on evidence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28447864.001).
  • [ISSN] 1473-0782
  • [Journal-full-title] The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
  • [ISO-abbreviation] Eur J Contracept Reprod Health Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Hyperandrogenism / acne / alopecia / cyproterone acetate / ethinylestradiol / hirsutism / polycystic ovary syndrome / seborrhea
  •  go-up   go-down


13. Katare OP, Raza K, Wadhwa S, Kumar P, Thotakura N: Dermatokinetics as an important tool to assess the bioavailability of drugs by topical nanocarriers. Curr Drug Metab; 2017 Mar 05;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To estimate the amount of drug delivery to skin, the scientists have now established techniques for separation of skin layers for the determination of drug concentrations.
  • This forms the basis of pharmacokinetics of drug(s) in skin, i.e., dermatokinetics.
  • Assessment of bioavailability helps in determination of safety and efficacy of topical formulations.
  • As the methods used for determination of pharmacokinetics of oral and intravenous formulations are not useful for dermatokinetic assessment, various methods like tape stripping, microdialysis and vasoconstrictor assays are being used for dermatokinetic assessment.These methods are not only useful to determine the drug concentrations in various skin layers, but can also be used to correlate the toxicity effects of xenobiotics with skin layer concentrations.
  • Despite advantages, there are some challenges in methodologies used for calculation of dermatokinetic parameters for furrows on skin and follicular drug penetration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
  • (PMID = 28266274.001).
  • [ISSN] 1875-5453
  • [Journal-full-title] Current drug metabolism
  • [ISO-abbreviation] Curr. Drug Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Pharmacokinetics / confocal microscopy / follicular drug penetration / micro dialysis / tape stripping / trypsin digestion / vasoconstrictor assay
  •  go-up   go-down


14. Lisante TA, Nunez C, Zhang P, Mathes BM: A 1% Colloidal Oatmeal Cream Alone is Effective in Reducing Symptoms of Mild to Moderate Atopic Dermatitis: Results from Two Clinical Studies. J Drugs Dermatol; 2017 Jul 01;16(7):671-676
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Such epidermal defects may be a trigger for AD, thereby encouraging research toward development of skin-barrier-targeted preventive strategies.
  • Study 1 assessed the Eczema Area and Severity Index (EASI) and Investigator's Global Atopic Dermatitis Assessment (IGADA) on day 3, and itch severity using a Visual Analogue Scale (VAS) immediately after application as primary efficacy endpoints.
  • In study 2, the primary efficacy endpoint was change from baseline in patients' assessment of itch.
  • Both studies assessed safety through adverse event (AE) recording.
  • Transepidermal water loss values were significantly reduced and skin hydration was significantly increased at all assessment time points.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28697218.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wilson SE, Graham DR, Wang W, Bruss JB, Castaneda-Ruiz B: Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies. Infect Dis Ther; 2017 Jul 10;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Concurrent Staphylococcus aureus bacteremia (SAB) worsens outcomes and increases mortality in patients with complicated skin and skin structure infections (cSSSI), hospital-acquired bacterial pneumonia, and ventilator-associated bacterial pneumonia (HABP/VABP).
  • METHODS: This retrospective analysis evaluated patients from the Assessment of Telavancin in Complicated Skin and Skin Structure Infections and Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia studies with baseline, concurrent SAB.
  • Differences in the clinical cure rates at test-of-cure and safety outcomes were compared for TLV vs vancomycin (VAN) treatment groups.
  • For both types of infections, the safety profile of TLV and VAN showed similar incidences of adverse events (AEs), serious AEs, or AEs leading to discontinuation.
  • CONCLUSION: This retrospective analysis demonstrated that TLV is clinically comparable in both efficacy and safety to VAN, and, therefore, may be an appropriate therapeutic option for the treatment of patients with HABP/VABP or cSSSI and concurrent SAB.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28695347.001).
  • [ISSN] 2193-8229
  • [Journal-full-title] Infectious diseases and therapy
  • [ISO-abbreviation] Infect Dis Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; Complicated skin and skin structure infection / Concurrent bacteremia / MRSA / Pneumonia / Staphylococcus aureus / Telavancin / Vancomycin
  •  go-up   go-down


16. Chi Y, Zheng Z, Zhou A, Yang L, Qu T, Jiang W, Shi S, Sun Y, Song Y, Kang S, Wang J: Randomized, single-centered, phase II clinical trial of nimotuzumab plus cisplatin and S-1 as first-line therapy in patients with advanced gastric cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e21021

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e21021 Background: Nimotuzumab, a humanized IgG1 anti-EGFR monoclonal antibody, has demonstrated efficacy associated with an absence of severe skin toxicity in many phase I/II cancer trials.
  • The primary endpoint was ORR and the secondary endpoints included TTP, PFS, 1-year survival rates and safety.
  • Up to 2011-01-14, 36 patients (NCS 19 cases compared with CS 17) have undergone efficacy assessment.
  • No adverse events of grade 3 skin rash or grade 3 infusion-related reactions were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Robert F, Verschraegen C, Hurwitz H, Uronis H, Advani R, Chen A, Taverna P, Wollman M, Fox J, Michelson G: A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients. J Clin Oncol; 2009 May 20;27(15_suppl):2536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoints: safety, tolerability, and DLT assessment.
  • Pharmacodynamic endpoint was inhibition of Histone H3 phosphorylation (pHH3) evaluated by immunohistochemistry of skin punch biopsies taken pre- and 2 hours post-infusion.
  • Inhibition of pHH3 by SNS-314 was observed in skin biopsies of patients treated at doses of 240 mg/m<sup>2</sup> and greater.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Scotte F, Tourani JM, Banu E, Peyromaure M, Jenabian A, Levy E, Coquelin K, Magherini E, Marsan S, Oudard S: Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study. J Clin Oncol; 2004 Jul 15;22(14_suppl):8003

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of frozen glove use in the prevention of docetaxel induced onycholysis and cutaneous reaction. Results of a multicenter case-control study.
  • : 8003 Background: Onycholysis and skin toxicity occur in about 15% of patients (pts) treated with docetaxel (D).
  • We investigated the efficacy and safety of an Elasto-Gel (Akromed, France) flexible frozen glove (FG) for the prevention of D-induced onycholysis and skin toxicity.
  • Onycholysis and skin toxicity were assessed at each cycle by NCI-CTC v.2 criteria and documented by photography.
  • Onycholysis and skin toxicity (main criteria) was significantly lower in the FG protected hand compared with the control hand (p=0.0001, Wilcoxon test).
  • Skin toxicity was G0: 73% vs. 41% and G1-2: 27% vs. 59% in the FG-protected hand and the control hand, respectively.
  • Median time to nail and skin toxicity occurrence was not significantly different between FG-protected and the control hand, respectively [106 days (5 cycles) vs. 58 days (2.7 cycles) for nail toxicity; 57 days vs. 58 days for skin toxicity].
  • CONCLUSIONS: Frozen glove significant reduces the nail and skin toxicity associated with docetaxel and provides a new tool in supportive care management for a better patient's quality of life.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015819.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Naqi N, Ahmad S, Murad S, Khattak J: A phase II feasibility study of sorafenib and gemcitabine combination therapy in advanced hepatocellular carcinoma. J Clin Oncol; 2011 Feb;29(4_suppl):298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to evaluate the efficacy and safety of sorafenib and gemcitabine combination in advanced HCC.
  • National Cancer Institute criteria for adverse events (NCI CTCAE) Version 3.0, and Response evaluation criteria for solid tumors (RECIST) was used for assessment.
  • 8 patients had progressive disease, 4 progressing on interim assessment were taken off protocol.
  • Sorafenib specific, hand foot skin reaction and anorexia were next most frequent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985679.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Dornic N, Ficheux AS, Bernard A, Roudot AC: Adequacy of the default values for skin surface area used for risk assessment and French anthropometric data by a probabilistic approach. Food Chem Toxicol; 2017 Aug;106(Pt A):386-392
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequacy of the default values for skin surface area used for risk assessment and French anthropometric data by a probabilistic approach.
  • The notes of guidance for the testing of cosmetic ingredients and their safety evaluation by the Scientific Committee on Consumer Safety (SCCS) is a document dedicated to ensuring the safety of European consumers.
  • This contains useful data for risk assessment such as default values for Skin Surface Area (SSA).
  • Probabilistic treatment of these data and analysis of the case of methylisothiazolinone, a sensitizer recently evaluated by a deterministic approach submitted to SCCS, suggest that the default value for SSA used in the quantitative risk assessment might not be relevant for a significant share of the French female population.
  • This is of importance given that some studies show an increasing risk of developping skin sensitization among women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28602598.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


21. Verner I, Kutscher TD: Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands. Lasers Med Sci; 2017 Jun 23;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of the efficacy and safety of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • This study evaluated the efficacy and safety of a novel technology, which combines bipolar radio frequency (RF) and optical energies for the cosmetic treatment of aging hands.
  • The objective of the study was to assess the efficacy, safety, tolerability, and patient satisfaction of combined bipolar radiofrequency and optical energies vs. optical energy alone for the treatment of aging hands.
  • Standardized clinical photographs were taken, and patient and investigator improvement assessment (Global Esthetic Improvement (GAI) scale), patient satisfaction, and tolerability were evaluated.
  • At the 1 and 3 months follow-up, skin laxity and pigmentation, investigator and patient improvement assessments, and satisfaction were significantly better in the hand treated with combined bipolar RF and IPL.
  • This study demonstrates the safety and efficacy of combining RF and optical energies for the esthetic improvement of aging hands.
  • Combined RF and IPL treatment was more efficient than IPL alone in improving skin pigmentation, skin laxity, and texture.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28643046.001).
  • [ISSN] 1435-604X
  • [Journal-full-title] Lasers in medical science
  • [ISO-abbreviation] Lasers Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Bipolar radiofrequency / Intense pulsed light / Laser / Noninvasive skin rejuvenation / Photo-damage / Pigmentary disorders
  •  go-up   go-down


22. Hoffman LK, Del Rosso JQ, Kircik LH: The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris. J Drugs Dermatol; 2017 Jun 01;16(6):534-538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris.
  • Given the advent of foam formulations with enhanced percutaneous absorption and convenient application due to easy spreadability on skin, the previously held idea that effective treatment of truncal acne requires oral treatment is challenged.
  • </p> <p>STUDY DESIGN: A single-center, open label pilot study was conducted to investigate the efficacy and safety of azelaic acid 15% foam as a treatment modality for moderate truncal acne.
  • </p> <p>RESULTS: Twice-daily application of azelaic acid 15% foam to affected areas resulted in a 1-grade reduction in truncal investigator global assessment (IGA) scores in nearly all patients (16/18).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28686770.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Zhang W, Chen L, Chen J, Wang L, Gui X, Ran J, Xu G, Zhao H, Zeng M, Ji J, Qian L, Zhou J, Ouyang H, Zou X: Silk Fibroin Biomaterial Shows Safe and Effective Wound Healing in Animal Models and a Randomized Controlled Clinical Trial. Adv Healthc Mater; 2017 May;6(10)

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here a silk fibroin film is developed and its translational potential is investigated for skin repair by performing comprehensive preclinical and clinical studies to fully evaluate its safety and effectiveness.
  • In vivo rabbit full-thickness skin defect study shows that the silk fibroin film effectively reduces the average wound healing time with better skin regeneration compared with the commercial wound dressings.
  • Subsequent assessment in porcine model confirms its long-term safety and effectiveness for full-thickness skin defects.
  • Therefore, the study provides systematic preclinical and clinical evidence that the silk fibroin film promotes wound healing thereby establishing a foundation towards its application for skin repair and regeneration in the clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
  • (PMID = 28337854.001).
  • [ISSN] 2192-2659
  • [Journal-full-title] Advanced healthcare materials
  • [ISO-abbreviation] Adv Healthc Mater
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; bench to bedside / controlled clinical trial / silk fibroin biomaterial / skin repair and regeneration / wound healing
  •  go-up   go-down


24. Munavalli G: A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients. J Drugs Dermatol; 2016 Nov 01;15(11):1335-1342
MedlinePlus Health Information. consumer health - Skin Aging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Split-Face Assessment of the Synergistic Potential of Sequential Q-Switched Nd:YAG Laser and 1565 nm Fractional Nonablative Laser Treatment for Facial Rejuvenation in Fitzpatrick Skin Type II-V Patients.
  • Recent appreciation of the multifactorial pathophysiology of skin aging has led to increased use of parallel treatment regimens.
  • This prospective, split-face, randomized study assessed the safety and efficacy of same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST) facial rejuvenation treatment in comparison to fractional non-ablative laser (NAFL) treatment only.
  • Immediate skin responses were assessed within 30 minutes of treatment, while wrinkle/elastosis scores, and skin tone and texture were evaluated 1, 3, and 6 months following the final treatment session.
  • Physician-evaluated skin tone and patient ratings of skin texture and overall improvement of the SST-treated side were consistently higher than the contralateral NAFL-treated side.
  • Although the SST regimen failed to demonstrate statistically signi cant clinical superiority over the NAFL regimen, the significantly lower pain levels, consistently higher physician and patient ratings following SST may justify its regular use as a skin rejuvenation technique.
  • [MeSH-major] Cosmetic Techniques. Laser Therapy / methods. Lasers, Solid-State / therapeutic use. Low-Level Light Therapy / methods. Rejuvenation. Skin Aging
  • [MeSH-minor] Aged. Combined Modality Therapy / adverse effects. Female. Follow-Up Studies. Humans. Middle Aged. Pain / etiology. Skin Pigmentation / physiology

  • MedlinePlus Health Information. consumer health - Piercing and Tattoos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095544.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung JW, Siedentop H, Molnar I, Schlumberger M: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. J Clin Oncol; 2013 Jun 20;31(18_suppl):4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The double-blind, randomized, multicenter phase III DECISION trial examined sorafenib efficacy and safety vs placebo in patients with progressive RAI-refractory DTC.
  • Secondary endpoints included overall survival (OS), response rate (RR; complete + partial response [PR]), and safety.
  • Tumor histology by independent assessment was 57% papillary, 25% follicular, and 10% poorly differentiated.
  • The most common any-grade treatment-emergent adverse events in the sorafenib arm included hand-foot skin reaction, diarrhea, alopecia, rash/desquamation, fatigue, weight loss and hypertension.
  • Tolerability was consistent with the known sorafenib safety profile.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28136058.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Musazzi UM, Franzè S, Minghetti P, Casiraghi A: Emulsion versus nanoemulsion: how much is the formulative shift critical for a cosmetic product? Drug Deliv Transl Res; 2017 May 15;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, nanoemulsions seemed to improve the penetration of active ingredients through the human skin, comparing to conventional emulsion.
  • In this contest, the risk of a higher systemic exposure of consumer to active ingredients, due to the ability of nanoemulsion to enhance permeation, results a critical attribute that should be evaluated for assuring the consumer safety.
  • The aim of this work was the evaluation of how an oil-in-water (O/W) nanoemulsion can influence the in vitro skin permeation profiles of two model active ingredients with different polarity (i.e., caffeine and ethyl ximenynate).
  • Considering such findings, it is worth observing that there is room for reconsidering the risk assessment of nanoemulsion-based cosmetic products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28508377.001).
  • [ISSN] 2190-3948
  • [Journal-full-title] Drug delivery and translational research
  • [ISO-abbreviation] Drug Deliv Transl Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Caffeine / Cosmetic / Ethyl ximenynate / Nanoemulsion / Risk assessment
  •  go-up   go-down


27. Frederick DM, Vorwerk L, Gupta A, Ghassemi A: Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin. Cutan Ocul Toxicol; 2017 Sep;36(3):263-272

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermal safety assessment of Arm & Hammer laundry products formulated for sensitive skin.
  • CONTEXT: The prevalence of sensitive skin among the general population in industrialized countries is reported to be over 50%.
  • Sensitive skin subjects often report significant reactions to contact with cosmetics, soaps and other consumer products.
  • OBJECTIVE: This paper describes the overall skin compatibility and mildness program for a newly developed, lightly fragranced, colorant free laundry product (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent), specially formulated for individuals with sensitive skin.
  • The skin mildness of the product was compared to Arm & Hammer™ Free & Clear liquid laundry detergent with no fragrance or colorant, and an established history of safe use by sensitive skin consumers.
  • MATERIALS AND METHODS: The test material was a liquid laundry product with a light scent formulated for sensitive skin consumers (Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent).
  • The product was compared to commercially marketed products for sensitive skin with a history of skin safety in the marketplace, including: a very similar product formulation (Arm & Hammer™ Free & Clear with no fragrance), and several selected competitors' products.
  • Studies were conducted among individuals with self-assessed sensitive skin (based on a questionnaire) using standard protocols for the Human Repeat Insult Patch Test (HRIPT), 10-Day Cumulative Irritation, the Wrist Band Wear test, and the Safety In-Use testing.
  • RESULTS: The HRIPT confirmed that neither the fragrance alone, nor the product formulation with fragrance, induced contact sensitization in sensitive skin subjects.
  • The 10-Day cumulative irritation study conducted using sensitive skin subjects showed highly favorable skin compatibility, and the test product was comparable to the control product (Arm & Hammer Free & Clear) and other nonirritant controls.
  • In the Wrist Band Wear test, exposure to laundered fabrics under exaggerated conditions gave similar results for the test and control products, with no objective signs of skin irritation, and no self-reported persistent adverse sensory effects.
  • The Safety In-Use tests evaluated 4-week exposure to product and laundered fabrics under realistic use conditions.
  • There were no clinically objective signs of skin irritation, and reports of transitory, mild sensory effects were minimal and similar for the test and controls.
  • DISCUSSION AND CONCLUSION: A comprehensive skin safety program on a lightly scented sensitive skin laundry formulation (i.e.
  • Arm & Hammer™ Sensitive Skin plus Skin-Friendly Fresh Scent) conducted among panels of self-assessed sensitive skin subjects demonstrated that the presence of a light fragrance did not adversely impact skin compatibility in any of the testing protocols when the product was compared to a similar product with no fragrance.
  • The lightly fragranced product demonstrated overall skin compatibility and mildness when tested in a self-assessed sensitive skin population, and compared favorably to currently marketed sensitive skin products.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28073339.001).
  • [ISSN] 1556-9535
  • [Journal-full-title] Cutaneous and ocular toxicology
  • [ISO-abbreviation] Cutan Ocul Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Consumer product safety / contact sensitization / cumulative irritation / safety in use test / sensitive skin / skin irritation / wrist band test
  •  go-up   go-down


28. Mei H, Yao P, Wang S, Li N, Zhu T, Chen X, Yang M, Zhuo S, Chen S, Wang JM, Wang H, Xie D, Wu Y, Le Y: Chronic low-dose cadmium exposure impairs cutaneous wound healing with defective early inflammatory responses after skin injury. Toxicol Sci; 2017 Jun 29;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic low-dose cadmium exposure impairs cutaneous wound healing with defective early inflammatory responses after skin injury.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28666365.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; cadmium / chemokine / neutrophil / proinflammatory cytokine / wound healing
  •  go-up   go-down


29. Clouet E, Kerdine-Römer S, Ferret PJ: Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references. Toxicol In Vitro; 2017 May 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references.
  • Allergic contact dermatitis (ACD) is an adverse health effect that develops following repeated exposure to skin sensitizing chemicals.
  • Here, we have selected an ITS (Integrated Testing Strategy) for skin sensitization which focuses on three in vitro methods that covered the first three steps of the AOP (DPRA, SENS-IS or h-CLAT).
  • The aim of this study was to compare these three methods due to the WoE approach based on a 2-out-of-3-assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2016. Published by Elsevier Ltd.
  • (PMID = 28539215.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; AOP / DPRA / ITS / SENS-IS / Skin sensitization / h-CLAT
  •  go-up   go-down


30. Hecht JR, Patnaik A, Malik I, Venook A, Berlin J, Croghan G, Wiens BL, Visonneau S, Jerian S, Meropol NJ: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3511

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This phase 2 study assessed the efficacy and safety of ABX-EGF monotherapy in pts with mCRC who previously failed therapy with a fluoropyrimidine and irinotecan or oxaliplatin or both.
  • Of 148 pts with evaluations after 8 weeks, 15 (10.1%; 95%CI: 5.8%, 16.2%) had confirmed partial responses (12 cohort A, 3 cohort B) and 54 (36.5%) had stable disease (39 cohort A, 15 cohort B) by investigator assessment.
  • The most frequent adverse event (AE) was skin rash (> 90%) [3.4% grade 3].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016465.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L, Crepy MN, Goncalo M, Macan J, Mahler V, Mijakoski D, Ramada Rodilla JM, Rustemeyer T, Spring P, John SM, Uter W, Wilkinson M, Giménez-Arnau AM: Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad Dermatol Venereol; 2017 Jun;31 Suppl 4:31-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum standards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe - position paper of the COST Action StanDerm (TD 1206).
  • BACKGROUND: Skin diseases constitute up to 40% of all notified occupational diseases in most European countries, predominantly comprising contact dermatitis, contact urticaria, and skin cancer.
  • While insufficient prevention of work-related skin diseases (WRSD) is a top-priority problem in Europe, common standards for prevention of these conditions are lacking.
  • OBJECTIVE: To develop common European standards on prevention and management of WRSD and occupational skin diseases (OSD).
  • Workplace exposure assessment of WRSD/OSD requires full labelling of product ingredients on material safety data sheets helping to identify allergens, irritants and skin carcinogens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28656728.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Politi Y, Levi A, Lapidoth M: Integrated Cooling-Vacuum-Assisted Non-Fractional 1540 nm Erbium:Glass Laser is Effective in Treating Acne Scars. J Drugs Dermatol; 2016 Nov 01;15(11):1359-1363
MedlinePlus Health Information. consumer health - Scars.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mid-infrared laser skin interaction is characterized by its modest absorption in water and nite penetration to the mid-dermis.
  • OBJECTIVES: To evaluate the safety and efficacy of acne scars treatment using an integrated cooling-vacuum-assisted 1540 nm Erbium: Glass Laser.
  • Average improvement was 3.9 and 4.1 points on the quartile scale used for outcome assessment 1 and 3 months following the last session, respectively.

  • MedlinePlus Health Information. consumer health - Acne.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28095548.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Campbell K, Baker B, Tovar A, Economos E, Williams B, McCauley L: The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers. Workplace Health Saf; 2017 Jul;65(7):313-321

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association Between Skin Rashes and Work Environment, Personal Protective Equipment, and Hygiene Practices Among Female Farmworkers.
  • The objective of this study was to assess work-related hygiene practices and the frequency and location of skin rashes due to cutaneous contact with crop-associated materials (e.g., pesticides) for female nursery and fernery workers in Central Florida.
  • A cross-sectional, community-based participatory research study of 237 female nursery and fernery workers between the ages of 19 and 43 years with significant cutaneous contact with foliage crops was conducted using a self-report questionnaire and a skin rash chart assessment tool.
  • Further research is needed to better understand the development of skin rashes among farmworkers, to generate effective prevention strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28628754.001).
  • [ISSN] 2165-0969
  • [Journal-full-title] Workplace health & safety
  • [ISO-abbreviation] Workplace Health Saf
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; disease prevention / government regulation / occupational hazards / occupational health and safety programs / workforce
  •  go-up   go-down


34. Sugino M, Hatanaka T, Todo H, Mashimo Y, Suzuki T, Kobayashi M, Hosoya O, Jinno H, Juni K, Sugibayashi K: Safety evaluation of dermal exposure to phthalates: Metabolism-dependent percutaneous absorption. Toxicol Appl Pharmacol; 2017 Aug 01;328:10-17
Hazardous Substances Data Bank. BUTYL BENZYL PHTHALATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety evaluation of dermal exposure to phthalates: Metabolism-dependent percutaneous absorption.
  • When dibutyl phthalate was applied to the skin of hairless rats and humans, only monobutyl phthalate appeared through the skin, and the permeability of the skin was higher than that after the application of the monoester directly.
  • The inhibition of skin esterases made the skin impermeable to the metabolite following dermal exposure to dibutyl ester, whereas removal of the stratum corneum from the skin did not change the skin permeation behavior.
  • The skin permeability of monobenzyl phthalate was higher than that of monobutyl phthalate in humans, although the reverse was observed in rats.
  • Species difference in skin permeation profile corresponded to the esterase activity of the skin homogenate.
  • Di(2-ethylhexyl) phthalate, which was not metabolized by esterases in the skin, was not transported across the skin.
  • Skin metabolism is essential to the percutaneous absorption of phthalates.
  • [MeSH-major] Environmental Pollutants / toxicity. Phthalic Acids / toxicity. Skin Absorption
  • [MeSH-minor] Animals. Dibutyl Phthalate. Diethylhexyl Phthalate / administration & dosage. Diethylhexyl Phthalate / pharmacokinetics. Diethylhexyl Phthalate / toxicity. Environmental Exposure. Esterases / antagonists & inhibitors. Female. Humans. In Vitro Techniques. Male. Middle Aged. Plasticizers / administration & dosage. Plasticizers / pharmacokinetics. Plasticizers / toxicity. Rats. Rats, Hairless. Risk Assessment. Skin / enzymology. Species Specificity

  • Hazardous Substances Data Bank. BIS(2-ETHYLHEXYL) PHTHALATE .
  • Hazardous Substances Data Bank. DIBUTYL PHTHALATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28506834.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Phthalic Acids; 0 / Plasticizers; 131-70-4 / monobutyl phthalate; 2286E5R2KE / Dibutyl Phthalate; C42K0PH13C / Diethylhexyl Phthalate; EC 3.1.- / Esterases; YPC4PJX59M / butylbenzyl phthalate
  • [Keywords] NOTNLM ; Dermal exposure / Metabolism / Phthalates / Risk identification / Skin permeation
  •  go-up   go-down


35. Dall'oglio F, Tedeschi A, Fusto CM, Lacarrubba F, Dinotta F, Micali G: A novel cosmetic antifungal/anti-inflammatory topical gel for the treatment of mild to moderate seborrheic dermatitis of the face: a open-label trial utilizing clinical evaluation and erythemadirected digital photography. G Ital Dermatol Venereol; 2017 Jan 24;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Advanced digital photography, equipped with technology able to provide a detailed evaluation of red skin components corresponding to vascular flare (erythema-directed digital photography), is a useful tool for evaluation of erythema in patients affected by inflammatory dermatoses.
  • The aim of this study was to assess the efficacy and safety of a new cosmetic topical gel containing ciclopiroxolamine, lactoferrin, glycero-phosphoinositol (GPI) and Aloe vera, for the treatment of facial seborrheic dermatitis by clinical and advanced digital photography evaluation.
  • Finally, at baseline and at the end of the study IGA (Investigator Global Assessment) was performed using a 5-point severity scale (from 0 =worsening to 4= excellent response).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121079.001).
  • [ISSN] 1827-1820
  • [Journal-full-title] Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
  • [ISO-abbreviation] G Ital Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Tolcher AW, Baird RD, Patnaik A, Moreno Garcia V, Papadopoulos KP, Garrett CR, Olmos D, Shannon KA, Zazulina V, Rubin EH, Smith IC, Ryan J, Smith PD, Taylor A, Learoyd M, Lupinacci L, Yan L, De Bono JS: A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol; 2011 May 20;29(15_suppl):3004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objectives of this phase I study were to examine the safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of the novel combination of MK-2206 with selumetinib.
  • In the MK-2206 QOD dosing schedule, dose-limiting Grade 3 macular skin rash was reported in 2/3 evaluable patients at MK-2206 45 mg QOD with selumetinib 75mg BID; the tolerable dose was MK-2206 45 mg QOD with selumetinib 75 mg QD.
  • Preliminary assessment of PK/PD data suggest no apparent drug-drug interactions with the PK profile of each drug administered in this combination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022185.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Ratain MJ, Flaherty KT, Stadler WM, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee RJ, Eisen T: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). J Clin Oncol; 2004 Jul 15;22(14_suppl):4501

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Typical drug-related toxicities were hand-foot skin reaction, rash, fatigue, diarrhea, anorexia and hypertension.
  • Of the 112 pts with RCC, 65 pts have reached the initial 12-week assessment (63 evaluable for response).
  • The randomized portion will provide information about BAY's disease-stabilizing effect and long-term safety, in particular in pts with RCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016014.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Thiesen LC, Baccarin T, Fischer-Muller AF, Meyre-Silva C, Couto AG, Bresolin TM, Santin JR: Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract. J Photochem Photobiol B; 2017 Feb;167:200-207
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photochemoprotective effects against UVA and UVB irradiation and photosafety assessment of Litchi chinensis leaves extract.
  • Actually, there has been an increase in the use of natural products as skin photoprotective agents.
  • Data herein obtained pointed out the potential of L. chinensis extract for photochemoprotection against UVA/UVB radiation and its damaging effects on human skin.
  • [MeSH-major] DNA Damage / drug effects. Litchi / chemistry. Plant Extracts / pharmacology. Plant Leaves / chemistry. Safety. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Safety.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28086120.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Plant Extracts; BBX060AN9V / Hydrogen Peroxide
  • [Keywords] NOTNLM ; Irritant / Litchi chinensis / Photochemoprotection / Photohaemolysis / Phototoxicity
  •  go-up   go-down


39. Adjadj L, SidAhmed-Mezi M, Mondoloni M, Meningaud JP, Hersant B: Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients. Plast Reconstr Surg; 2017 Jul;140(1):50-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the Efficacy of Cryolipolysis on Saddlebags: A Prospective Study of 53 Patients.
  • The main objective of this study was to demonstrate the efficacy, patient tolerance, and safety of cryolipolysis on the saddlebags.
  • Reversible skin changes such as postprocedure postinflammatory hyperpigmentation were observed in 8.33 percent of patients.
  • A substantial risk of skin lesions, including postinflammatory hyperpigmentation that resolved after a few months, was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28654588.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Lai PM, Collaku A, Reed K: Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial. J Int Med Res; 2017 Apr;45(2):647-661
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of topical diclofenac/menthol gel for ankle sprain: A randomized, double-blind, placebo- and active-controlled trial.
  • Secondary outcomes included pain relief (PR); PI; time to onset of PR, meaningful PR, cooling, and complete recovery; PI difference; sum of PI difference; total PR; reduction in ankle swelling; and the patient's global assessment of response to treatment.
  • There was a higher incidence of skin and application-site events with 1% diclofenac/3% menthol than with placebo or 1% diclofenac.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28345425.001).
  • [ISSN] 1473-2300
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ankle sprain / diclofenac / menthol / pain / topical administration
  •  go-up   go-down


41. Petry T, Bosch A, Coste X, Eigler D, Germain P, Seidel S, Jean PA: Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes. Regul Toxicol Pharmacol; 2017 Mar;84:64-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes.
  • The skin sensitization potential of chemicals has traditionally been evaluated in vivo according to OECD testing guidelines in guinea pigs or the mouse local lymph node assay.
  • There has lately been a great emphasis on establishing in vitro test methods reflecting the key biological events in the adverse outcome pathway (AOP) for skin sensitization as published by the OECD.
  • Against this background, a group of 8 polysiloxanes and silanes, seven of them aminofunctionalised, for which in vivo data were already available, has been tested in vitro in the direct peptide reactivity assay (DPRA), the KeratinoSens™ and the human cell line activation test (h-CLAT) and in the modified myeloid U937 skin sensitization test (mMUSST) as far as technically feasible.
  • The data also allow for a preliminary evaluation of proposed integrated testing strategies (ITS) to determine the skin sensitization potential of chemicals which were not considered in the training sets of the respective ITS.
  • [MeSH-major] Biological Assay. Dendritic Cells / drug effects. Dermatitis, Allergic Contact / etiology. Irritants / toxicity. Keratinocytes / drug effects. Silanes / toxicity. Siloxanes / toxicity. Skin Irritancy Tests / methods
  • [MeSH-minor] Animal Testing Alternatives. Animals. Feasibility Studies. Gene Expression Regulation / drug effects. Genes, Reporter. Guinea Pigs. Humans. Local Lymph Node Assay. Mice, Inbred CBA. Risk Assessment. U937 Cells

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28017767.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Irritants; 0 / Silanes; 0 / Siloxanes
  • [Keywords] NOTNLM ; DPRA (major topic) / GPMT (major topic) / In vitro (major topic) / KeratinoSens™ (major topic) / LLNA (major topic) / Polysiloxanes (major topic) / Sensitization (major topic) / Silanes (major topic) / h-CLAT (major topic) / mMUSST (major topic)
  •  go-up   go-down


42. Monastirli A, Pasmatzi E, Badavanis G, Tsambaos D: Gestational Pityriasis Rosea: Suggestions for Approaching Affected Pregnant Women. Acta Dermatovenerol Croat; 2016 Dec;24(4):312-313

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All miscarrying women reportedly revealed an aggressive course of widespread eruption and severe constitutional symptoms; all of them had HHV-6 DNA in the plasma, placenta, skin lesions, and fetal tissues, whereas HHV-7 DNA was detected in the plasma and skin lesions in 3 out of 8 (37.5%) miscarrying women.
  • HHV-6 DNA was found only in the plasma of 2 out of 31 women (6.45%) with normal pregnancy, whereas HHV-7 DNA was detected in the plasma of 3 (9.45%) and in the skin lesions of 2 women (6.45%) with normal pregnancy.
  • 4. Reliable and definite data from adequate and controlled human studies on the safety of acyclovir or valacyclovir in pregnant women and their efficacy in pityriasis rosea are lacking.
  • Thus, the decision on whether these antiviral compounds will be administered should be tailored to each individual pregnant woman, subsequent to a meticulous assessment of the potential risks and their balancing against the potential benefits.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28128088.001).
  • [ISSN] 1847-6538
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


43. Jaffray D, Mutic S, Fallone B, Raaymakers B: MO-A-WAB-01: MRI-Guided Radiation Therapy. Med Phys; 2013 Jun;40(6Part23):390

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The concept of integrating a magnetic resonance imaging (MRI) scanner with a therapy radiation source, either a therapy linear accelerator (linac) or <sup>60</sup> Co, emerged as a feasible novel approach for MRI-guided radiation therapy (i.e.
  • MRI offers the capability to visualize soft-tissue as well as to perform physiological assessment of healthy and tumor tissues.
  • Multiple interdependent issues need to be resolved in order to achieve the optimal operation of the MRI scanner and the radiation source(s) such as: a) radiofrequency (RF) interference, b) magnetic field coupling, c) perturbation of the dose deposited in tissue due to the presence of an external magnetic field, and d) escalation of patient skin dose.
  • They will also discuss key aspects related to the clinical implementation of their systems such as safety, applications, workflows, quality control, staffing models for supporting the infrastructure, and preliminary data.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28518368.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Dosimetry / Linear accelerators / Magnetic fields / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Radiation therapy / Radiation treatment / Radiotherapy sources / Tissues
  •  go-up   go-down


44. Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P: Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med; 2017 May;83(8):710-717

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ECa 233, a standardized extract of <i>Centella asiatica</i>, has been found to exhibit various positive neurological effects and to have a good safety profile.
  • The results showed that all animals had a good tolerability for ECa 233, whereas madecassic and asiatic acids were found in negligible amounts after pharmacokinetic assessment.
  • Both triterpenoids were extensively distributed in the brain, stomach, and skin within 1 h and remained there for at least 4 h after dosing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart · New York.
  • (PMID = 27992940.001).
  • [ISSN] 1439-0221
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ECa 233 extract; 0 / Plant Extracts; 0 / Triterpenes; 34540-22-2 / madecassoside; PKO39VY215 / asiaticoside
  •  go-up   go-down


45. Wohlrab J, Gilbrich F, Wolff L, Fischer M, Philipp S: [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch]. Hautarzt; 2016 Dec 15;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preclinical safety evaluation of chloral hydrate after topical application using the example of psoriatic itch].
  • OBJECTIVES: For lack of clinical safety data, preclinical tests for cutaneous cytotoxicity and calculations for systemic bioavailability after topical application have been performed.
  • CONCLUSION: The present data cannot fully remove safety concerns for topical application of chloral hydrate in the formulation favoured by the NRF (Neues Rezepturformularium)-the so-called 1‑2-3-cream.
  • For a better assessment of harmlessness, tests for cutaneous bioavailability (concentration-time profile) on human skin and clinical studies would be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27981385.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Journal Article; English Abstract
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Administration / Antipruritics / Bioavailability / Cytotoxicity / Psoriasis
  •  go-up   go-down


46. Farah J, Trianni A, Carinou E, Dabin J, Deangelis C, Domienik J, Knezevic Z, Kopec R, Malchair F, Negri A, Novak L, Siiskonen T, Vanhavere F, Clairand I: SU-E-I-28: Assessment of Maximum Patient Skin Dose for Interventional Radiology Procedures: Method and Uncertainty Analysis. Med Phys; 2013 Jun;40(6Part5):131

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SU-E-I-28: Assessment of Maximum Patient Skin Dose for Interventional Radiology Procedures: Method and Uncertainty Analysis.
  • PURPOSE: To develop a method for the assessment of patient's maximum skin dose in interventional radiology procedures.
  • METHODS: In the framework of EURADOS WG12, a European measurement protocol was developed to determine fluoroscopy patient skin dose for interventional procedures.
  • The method investigates the use of XR-RV3 gafchromic films, punctual TLDs and TLD sheets to intercept the X-ray beam and measure the maximum skin dose.
  • RESULTS: XR-RV3 films, being large area dosemeters, proved to reproduce with good accuracy the dose distribution over the patient skin.
  • Nonetheless, significant dependence with beam energy and quality, reading and fitting process was observed, which introduces important uncertainties in maximum skin dose measurement.
  • Meanwhile, TLDs enabled precise dose estimates with lower uncertainty values but point TLD detectors may implicate missing the maximum dose location on the patient skin.
  • Thus, TLD sheets could represent the most adapted tool for the assessment of fluoroscopy-induced skin doses.
  • CONCLUSION: The developed protocol standardizes practices of patient skin dose estimates in interventional radiology.
  • Based on these results, the assessment, at European level, of alerts for interventional procedures using real-time Kerma-Area Product and Cumulative Air Kerma as skin dose indicators will be carried out.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2013 American Association of Physicists in Medicine.
  • (PMID = 28519344.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Backscattering / Calibration / Data analysis / Dosimetry / Error analysis / Fluoroscopy / Medical physicists / Polynomials / Position sensitive detectors / Thermoluminescent dosimeters
  •  go-up   go-down


47. Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, Danilenko DM, Arora P, Wang X, Ouyang W: IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice. PLoS One; 2017;12(1):e0170639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mechanistically, when compared to other growth factors such as VEGF and PDGF that accelerate wound healing in this model, IL-22 uniquely induced genes involved in reepithelialization, tissue remodeling and innate host defense mechanisms from wounded skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 Jan 12;104(1):9-19 [11163236.001]
  • [Cites] N Engl J Med. 1999 Sep 2;341(10):738-46 [10471461.001]
  • [Cites] Cytokine. 2013 Jun;62(3):360-8 [23582717.001]
  • [Cites] J Invest Dermatol. 2012 Jun;132(6):1717-24 [22358061.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):1080-7 [16936280.001]
  • [Cites] J Invest Dermatol. 2015 Nov;135(11):2862-70 [26168231.001]
  • [Cites] Biologics. 2008 Mar;2(1):1-12 [19707423.001]
  • [Cites] J Immunol. 2001 Oct 1;167(7):3545-9 [11564763.001]
  • [Cites] Nat Rev Immunol. 2014 Dec;14(12):783-95 [25421700.001]
  • [Cites] Genome Res. 2003 Nov;13(11):2498-504 [14597658.001]
  • [Cites] Am J Surg. 1998 Aug;176(2A Suppl):48S-54S [9777972.001]
  • [Cites] Sci Transl Med. 2014 Feb 12;6(223):223ra22 [24523322.001]
  • [Cites] Lancet. 2003 May 3;361(9368):1545-51 [12737879.001]
  • [Cites] Nature. 2014 Oct 9;514(7521):237-41 [25119041.001]
  • [Cites] Wound Repair Regen. 2007 Sep-Oct;15(5):665-70 [17971012.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1235-46 [2356856.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7341-7 [11706020.001]
  • [Cites] BMC Microbiol. 2008 Mar 06;8:43 [18325110.001]
  • [Cites] Nat Immunol. 2011 Aug 28;12(10):941-8 [21874025.001]
  • [Cites] Organogenesis. 2011 Jul-Sep;7(3):202-8 [22041517.001]
  • [Cites] Sci Transl Med. 2011 Dec 14;3(113):113ra126 [22174314.001]
  • [Cites] Stat Med. 1990 Jul;9(7):811-8 [2218183.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47517-23 [12351624.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1736-43 [16291068.001]
  • [Cites] World J Diabetes. 2014 Aug 15;5(4):546-56 [25126400.001]
  • [Cites] Surgeon. 2007 Aug;5(4):219-31 [17849958.001]
  • [Cites] Front Biosci. 2004 Jan 01;9:283-9 [14766366.001]
  • [Cites] J Biol Chem. 2000 Oct 6;275(40):31335-9 [10875937.001]
  • [Cites] Nat Med. 2008 Mar;14(3):275-81 [18264110.001]
  • [Cites] J Invest Dermatol. 2013 May;133(5):1321-9 [23223145.001]
  • [Cites] Nat Med. 2008 Mar;14(3):282-9 [18264109.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1219-22 [17476353.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1719-24 [16291066.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):835-70 [12843410.001]
  • [Cites] J Invest Dermatol. 2000 Aug;115(2):234-44 [10951241.001]
  • [Cites] Wound Repair Regen. 2004 Jul-Aug;12(4):485-92 [15260814.001]
  • [Cites] Clin Dermatol. 2007 Jan-Feb;25(1):9-18 [17276196.001]
  • [Cites] Bioinformatics. 2007 Jan 15;23(2):257-8 [17098774.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):1935-47 [15161630.001]
  • [Cites] J Biomed Biotechnol. 2011;2011:969618 [21151647.001]
  • [Cites] World J Diabetes. 2015 Feb 15;6(1):37-53 [25685277.001]
  • [Cites] Lancet. 2005 Nov 12;366(9498):1725-35 [16291067.001]
  • [Cites] J Immunol. 2007 Feb 15;178(4):2229-40 [17277128.001]
  • [Cites] Clin Plast Surg. 2003 Jan;30(1):1-12 [12636211.001]
  • [Cites] J Immunol. 2005 Mar 15;174(6):3695-702 [15749908.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 25;107(21):9546-51 [20460310.001]
  • [Cites] Wound Repair Regen. 2008 Sep-Oct;16(5):585-601 [19128254.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1309-23 [16619290.001]
  • [Cites] Immunity. 2008 Apr;28(4):454-67 [18400188.001]
  • (PMID = 28125663.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Palmieri C, Stein RC, Liu X, Hudson E, Nicholas H, Sasano H, Guestini F, Holcombe C, Barrett S, Kenny L, Reed S, Lim A, Hayward L, Howell S, Coombes RC, IRIS trial participants: IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Res Treat; 2017 Jun 13;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed a multicentre, open label phase II trial of the addition of Irosustat to a first-line aromatase inhibitor (AI) in patients with advanced BC to evaluate the safety of the combination and to test the hypothesis that the addition of Irosustat to AI may further suppress estradiol levels and result in clinical benefit.
  • Secondary endpoints included safety, tolerability, and pharmacodynamic end points.
  • RESULTS: Twenty-seven women were recruited, four discontinued treatment without response assessment.
  • The most frequently reported grade 3/4 toxicities were dry skin (28%), nausea (13%), fatigue (13%), diarrhoea (8%), headache (7%), anorexia (7%) and lethargy (7%).
  • CONCLUSIONS: The addition of Irosustat to aromatase inhibitor therapy resulted in clinical benefit with an acceptable safety profile.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28612226.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Aromatase / Breast cancer / Endocrine therapy / Sulfatase
  •  go-up   go-down


49. Jubbal KT, Zavlin D, Buchanan EP, Hollier LH Jr: Analysis of risk factors associated with unplanned reoperations following pediatric plastic surgery. J Plast Reconstr Aesthet Surg; 2017 May 18;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/PURPOSE: Unplanned reoperation (UR) is an outcome measure with multiple advantages that can be used as a standardized tool to assess an institution's quality and safety of medical care.
  • The procedures most commonly associated with UR were excision of skin and subcutaneous tissue for hidradenitis (UR = 10.3%), forehead, and/or supraorbital rim reconstruction with grafts (allograft or prosthetic material, UR = 6.1%), use of multiplane external fixators (UR = 5.6%), mastectomy for gynecomastia (UR = 4.4%), and forehead and/or supraorbital rim reconstruction with autograft (3.3%).
  • These results may aid in the informed consent process, improve patient risk assessment, counseling, and surgical planning.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 28595843.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Outcomes / Pediatric / Plastic surgery / Reoperation
  •  go-up   go-down


50. Friedman PM, Tolkachjov SN, Geddes ER, Tillman KA, Zachary CB: TRASER: An innovative device for the treatment of nasal telangiectasias. Lasers Surg Med; 2017 Apr 06;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of a novel configurable device in the treatment of nasal telangiectasias.
  • METHODS: Fifteen subjects aged 42-73 with Fitzpatrick skin types I and II were treated for nasal telangiectasias of various sizes.
  • Efficacy was measured by blinded analysis of pre and post images and self-assessment by the subjects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382712.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; TRASER / Total Reflection Amplification of Spontaneous Emission Radiation / pulse dye laser / pyrromethene / telangiectasias / total internal reflection / tunable wavelength / variable pulse duration
  •  go-up   go-down


51. Baselga J, Schwartzberg LS, Petrenciuc O, Shan M, Gradishar WJ: Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC). J Clin Oncol; 2011 May 20;29(15_suppl):TPS124

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most drug-related adverse events were grade 1/2 in severity with the exception of grade 3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% in SOR+CAP vs 14% in PL+CAP).
  • Radiographic assessment is every 6 wk for the first 36 wk, and every 9 wk thereafter.
  • Secondary endpoints include overall survival, time to progression, overall response rate, duration of response (RECIST 1.1 criteria), and safety.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28022937.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Shen Y, Hsu C, Hsu C, Lin Z, Chen P, Shao Y, Huang T, Ding Y, Cheng A: A phase II study of sorafenib in combination with tegafur/uracil (UFT) for Asian patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol; 2009 May 20;27(15_suppl):4589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase II study to evaluate the efficacy and safety of sorafenib plus low-dose UFT in advanced HCC patients (pts).
  • Tumor assessment was performed q8w by RECIST criteria.
  • Hand-foot skin reaction (HFSR), fatigue, and diarrhea were most common AEs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963091.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Derby BM, Codner MA: Evidence-Based Medicine: Face Lift. Plast Reconstr Surg; 2017 Jan;139(1):151e-167e

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3. Incorporate risk-reduction strategies during preoperative assessment.
  • 6. Incorporate use of valid patient outcomes assessment tools in their practice to facilitate standardized outcomes reporting in the face-lift literature.
  • SUMMARY: Treating the aged face requires an understanding of bone and soft-tissue anatomy, including the analogous lamellar layers of the face and neck, and the techniques designed to restore youthful skin tone and facial contours.
  • [MeSH-minor] Evidence-Based Medicine. Face / anatomy & histology. Facial Nerve / anatomy & histology. Female. Humans. Male. Patient Safety. Postoperative Complications / prevention & control. Preoperative Care

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28027252.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


54. Gage R, Leung W, Stanley J, Reeder A, Barr M, Chambers T, Smith M, Signal L: Clothing Protection from UVR: A New Method for Assessment. Photochem Photobiol; 2017 Jun 13;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clothing Protection from UVR: A New Method for Assessment.
  • Clothing modifies ultraviolet radiation exposure from the sun, and has an impact on skin cancer risk and the endogenous synthesis of vitamin D<sub>3</sub> .
  • Diagrams displaying each clothing item were developed and incorporated into a coverage assessment procedure (CAP).
  • Values of clothing coverage, inter-rater reliability and assessment time were compared between CAP and Lund & Browder methods.
  • Its use could improve comparability between sun-safety studies and aid in quantifying the health effects of ultraviolet radiation exposure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] This article is protected by copyright. All rights reserved.
  • (PMID = 28608526.001).
  • [ISSN] 1751-1097
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Bil W, Schuur AG, Ezendam J, Bokkers BGH: Probabilistic derivation of the interspecies assessment factor for skin sensitization. Regul Toxicol Pharmacol; 2017 May 22;88:34-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probabilistic derivation of the interspecies assessment factor for skin sensitization.
  • An interspecies sensitization assessment factor (SAF) is used in the quantitative risk assessment (QRA) for skin sensitization when a murine-based NESIL (No Expected Sensitization Induction Level) is taken as point of departure.
  • It can be concluded that a murine-based NESIL requires the use of an interspecies SAF (of 15) in the QRA for skin sensitization, to correct for the differences between mice and humans.
  • This empirically derived interspecies SAF contributes to refinement of the risk assessment methodology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Inc. All rights reserved.
  • (PMID = 28545776.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Allergic contact dermatitis / Dose-response modeling / HMT / HRIPT / Interspecies sensitization assessment factor / LLNA / Probability distribution / Quantitative risk assessment / Skin sensitization
  •  go-up   go-down


56. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass H, Dietzfelbinger HF, Oruzio DV, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf HW, Mittermueller J, Haberl C, Giessen CA, Moosmann N, Stintzing S: Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial. J Clin Oncol; 2011 May 20;29(15_suppl):3589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer (mCRC): AIO KRK-0104 trial.
  • : 3589 Background: The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of two capecitabine-based regimens: CAPIRI plus cetuximab (CAPIRI-C) and CAPOX plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC).
  • Treatment related skin toxicity was evaluated separately for capecitabine and cetuximab.
  • The present analysis investigates the correlation of capecitabine-attributed skin toxicity (Cape-ST) and parameters of treatment efficacy.
  • RESULTS: Of 185 recruited patients, 149 patients (CAPIRI-C, n=78; CAPOX-C, n=71) received study treatment beyond the first tumor assessment and were evaluable for efficacy.
  • While cetuximab-specific skin toxicity such as acneiform rash, dry skin and others occurred in >90% of patients, Cape-ST, predominantly hand-foot syndrome, was observed in only 33.2% of patients.
  • CONCLUSIONS: This analysis supports the hypothesis that for the evaluated regimens a correlation exists between capecitabine-specific skin toxicity and treatment efficacy regarding DCR, PFS and OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28020253.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Guarneri A, Cioni M, Rongioletti F: High-dose intravenous immunoglobulin therapy for scleromyxoedema: a prospective open-label clinical trial using an objective score of clinical evaluation system. J Eur Acad Dermatol Venereol; 2017 Mar 29;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the safety and efficacy of high-dose intravenous immunoglobulin (IVIg) for the management of scleromyxoedema prospectively using an objective score.
  • The patients were followed-up to a minimum of 6 months, and their disease activity and response to treatment were assessed using the Physician's Global Assessment of disease severity (PGA) and a modified objective skin scoring system for patients with scleroderma (modified Rodnan score system for scleromyxoedema or mRSSS).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28370513.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Duvic M, Ziari S, Olsen EA, Foss FM: Phase 1-2 multi-center study of intravenous Bcx-1777 in patients with refractory cutaneous T-cell lymphoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):6733

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6733 Background: Cutaneous T-cell lymphomas (CTCL) including the leukemic variant, Sezary Syndrome (SS) are incurable extra-nodal non-Hodgkin's lymphomas caused by accumulation of skin homing T-cells.
  • Clinical response was determined each course using a weighted composite of disease assessment from baseline.
  • Safety visits were conducted weekly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014492.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Roberts DW, Aptula A, Api AM: Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis. Chem Res Toxicol; 2017 Feb 20;30(2):524-531

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Epoxides are known or proposed to be involved in skin sensitization in various ways.
  • To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of S<sub>N</sub>2 electrophiles.
  • The epoxide QMM predicts the potency of a nonepoxide S<sub>N</sub>2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar S<sub>N</sub>2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28121139.001).
  • [ISSN] 1520-5010
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Zapletalova A, Pata V, Janis R, Kejlova K, Stoklasek P: Objective measurements of skin surface roughness after microdermabrasion treatment. Skin Res Technol; 2017 Aug;23(3):346-353

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Objective measurements of skin surface roughness after microdermabrasion treatment.
  • BACKGROUND: The aim of this article is to present a new methodology for assessment of skin topology using a three-dimensional image (3D).
  • METHODS: The measurement of the skin surface roughness is based on 3D scanning of silicone replicas by chromatic aberration length technique in a contactless manner, i.e. by a polychromatic light beam.
  • Analysis of the skin surface reprints was performed using Talymap, Gold version.
  • Results were analysed by fractal geometry, which allows to evaluate changes of the skin surface before and after application of cosmetics and instrumental cosmetological techniques.
  • The methodology was applied for objective assessment of the effects of diamond microdermabrasion on the skin surface roughness.
  • RESULTS: Based on the results of skin surface scanning after the treatment with diamond microdermabrasion it may be concluded that inequalities of the skin surface are reduced immediately after exfoliation.
  • The entire study ultimately suggests that the instrumental method used only leads to improvement of the skin surface immediately after its application.
  • Thermo vision images of the skin surface temperature were obtained during the application of the abrasive method.
  • The experimental results showed that the skin is rather cooled than heated by the treatment.
  • CONCLUSION: This study is focused on the development of a methodology for objective measurement of changes in treated skin relief using 3D scanning.
  • The output may also include also an enlarged model of the skin surface made by 3D printer, which can serve for illustrative communication with the client.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
  • (PMID = 28083897.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3D scanning / claim substantiation / microdermabrasion / replication / skin structure / statistics
  •  go-up   go-down


61. Barbero AM, Frasch HF: Effect of stratum corneum heterogeneity, anisotropy, asymmetry and follicular pathway on transdermal penetration. J Control Release; 2017 Jun 29;260:234-246

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A quantitative and thorough study of skin permeation is essential for chemical exposure assessment and transdermal delivery of drugs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier B.V.
  • (PMID = 28596104.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Corneocyte / Diffusion / Lag time / Lipid bilayers / Partition coefficient / Skin appendages
  •  go-up   go-down


62. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, Johnson D, Fleishman A, Lee S, Takeshita K: ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7083

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a report of results from part 1 of a 2-part, phase 2 trial to evaluate the efficacy, safety, and pharmacokinetics (PK) of ABX-EGF in combination with paclitaxel and carboplatin for advanced NSCLC.
  • One pt (5%) had a confirmed complete response (1.0 mg/kg) and 4 pts (21%) had partial responses (2 at 2.0 mg/kg and 2 at 2.5 mg/kg) by investigator assessment.
  • The most common adverse event (AE) was skin rash (89% overall; 83%, 100%, and 83% in the 1.0, 2.0, and 2.5 mg/kg groups).
  • The incidence of grade 3 skin rash did not appear to increase with dose (17% at 1.0 mg/kg, 29% at 2.0 mg/kg, and 0% at 2.5 mg/kg).
  • Four pts (1 at 1.0 mg/kg and 3 at 2.0 mg/kg) had ABX-EGF dosing interrupted or reduced because of skin toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016137.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Yu Y, Li L, Li H, Yu X, Zhang Y, Wang Q, Zhou Z, Gao D, Ye H, Lin B, Ma R: In vivo assessment of dermal adhesion, penetration, and bioavailability of tetrabromobisphenol A. Environ Pollut; 2017 Sep;228:305-310

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo assessment of dermal adhesion, penetration, and bioavailability of tetrabromobisphenol A.
  • The skin adhesion coefficient (AC) was calculated using a difference-value method and ranged from 0.12 to 3.25 mg/cm<sup>2</sup> and 0.1 to 2.56 mg/cm<sup>2</sup> for the male and female rats, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28550799.001).
  • [ISSN] 1873-6424
  • [Journal-full-title] Environmental pollution (Barking, Essex : 1987)
  • [ISO-abbreviation] Environ. Pollut.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Adhesion / Bioavailability / Dermal exposure / Penetration / Tetrabromobisphenol A
  •  go-up   go-down


64. Cohn AL, Smith DA, Neubauer MA, Houston G, Khandelwal P, Wiggans RG, Zhang K, Yassine M: Results from panitumumab (pmab) regimen evaluation in colorectal cancer to estimate primary response to treatment (PRECEPT): Second-line treatment with pmab and FOLFIRI by tumor KRAS status. J Clin Oncol; 2009 May 20;27(15_suppl):4067

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Efficacy (objective response, progression-free survival [PFS], and overall survival [OS]) and safety were evaluated by KRAS status.
  • RESULTS: In an interim analysis (May 2008) of 115 pts who had received ≥ 1 dose of pmab, 109 pts had known KRAS status (59% had tumors with wild-type [WT] KRAS, 41% had mutant [MT] KRAS tumors), and 102 pts had the opportunity to have their first tumor assessment.
  • Most common AEs were skin-related toxicities (86% of pts), diarrhea (72%), and nausea (53%); there was no evidence that incidence of AEs was related to KRAS status.
  • Pmab had a safety profile consistent with other FOLFIRI + pmab trials.
  • Final efficacy and safety data will be presented.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Skowron K, Jakubicz A, Budzyńska A, Kaczmarek A, Grudlewska K, Reśliński A, Gospodarek-Komkowska E: Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date. Rocz Panstw Zakl Hig; 2017;68(2):191-197

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microbiological purity assessment of cosmetics used by one and several persons and cosmetics after their expiry date
  • Background: Microbiological purity of cosmetics provides safety of users during their use, prevents physicochemical changes of a preparation, infections and diseases of the skin.
  • Objective: The aim of this study was to assess the level of microbiological contamination of cosmetics used by one person and by several people and cosmetics after their expiry date in relations to standards for marketed cosmetics, ensuring safety of their use.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28646837.001).
  • [ISSN] 0035-7715
  • [Journal-full-title] Roczniki Panstwowego Zakladu Higieny
  • [ISO-abbreviation] Rocz Panstw Zakl Hig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


66. Cheng CY, Huang YL, Lee MC, Chang SL, Lin YF, Hu S: Pulsed alexandrite laser for treatment of melasma in Asian patients. J Cosmet Laser Ther; 2017 Aug;19(4):210-214

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present study was conducted to evaluate the efficacy and safety of pulsed alexandrite laser for the treatment of melasma.
  • The severity of melasma was evaluated by a blinded dermatologist, using the Modified Melasma Area and Severity Index (MMASI), and by patient assessment, using a visual analogue scale, at baseline, before each treatment, and at the 1-month and 3-month follow-up visits after the last treatment.
  • The treatments were well tolerated with only mild skin reaction.
  • CONCLUSION: In the present study, we demonstrated that the pulsed alexandrite laser is safe and effective to treat melasma in Asian skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151024.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alexandrite laser / Asian / melasma
  •  go-up   go-down


67. Helmer E, Watling M, Jones E, Tytgat D, Jones M, Allen R, Payne A, Koch A, Healy E: First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases. Eur J Clin Pharmacol; 2017 May;73(5):581-591
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These studies aimed to investigate the safety, tolerability and PK profile of seletalisib, a selective inhibitor of PI3Kδ in humans.
  • Pharmacodynamic effects on markers of inflammation were assessed via changes in ex vivo basophil degranulation and histological assessment of psoriatic skin biopsies.
  • No safety concerns or dose-limiting toxicities were identified (Study-1).
  • Pharmacodynamic findings demonstrated ex vivo inhibition of basophil degranulation, improvements in histological assessment of skin biopsies and other markers of psoriatic biology and preliminary evidence of target engagement in psoriatic skin tissue.
  • CONCLUSIONS: Seletalisib safety, tolerability and pharmacokinetic/pharmacodynamic profiles support its continued clinical development in immune-inflammatory diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Allergy Clin Immunol. 1976 Dec;58(6):676-82 [993482.001]
  • [Cites] Cell Death Dis. 2012 Jun 28;3:e334 [22739986.001]
  • [Cites] Am J Clin Dermatol. 2014 Oct;15(5):379-85 [25027461.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2203-13 [20081091.001]
  • [Cites] Curr Opin Pharmacol. 2015 Aug;23:82-91 [26093105.001]
  • [Cites] Int J Rheum Dis. 2014 May;17(4):359-68 [24460872.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):79-88 [18633443.001]
  • [Cites] Cell Signal. 2011 Apr;23(4):603-8 [20940048.001]
  • [Cites] J Autoimmun. 2011 May;36(3-4):278-87 [21396797.001]
  • [Cites] J Invest Dermatol. 2007 Oct;127(10):2445-52 [17495954.001]
  • [Cites] Ann N Y Acad Sci. 2013 Mar;1280:24-6 [23551098.001]
  • [Cites] J Immunol. 2012 Nov 1;189(9):4612-20 [23024273.001]
  • [Cites] J Invest Dermatol. 2008 May;128(5):1064-7 [18408745.001]
  • [Cites] Trends Immunol. 2007 Feb;28(2):80-7 [17208518.001]
  • [Cites] Open Rheumatol J. 2012;6:245-58 [23028409.001]
  • [Cites] Br J Dermatol. 2014 Jan;170(1):59-65 [24117368.001]
  • [Cites] J Invest Dermatol. 2014 Jan;134(1):268-71 [23812303.001]
  • [Cites] Arch Dermatol Res. 2011 Dec;303(10):691-705 [21863252.001]
  • [Cites] Rheumatology (Oxford). 2015 Feb;54(2):219-30 [25342375.001]
  • [Cites] Rheumatology (Oxford). 2012 Mar;51(3):552-6 [22120603.001]
  • [Cites] J Immunol. 2008 Feb 15;180(4):2538-44 [18250464.001]
  • [Cites] N Engl J Med. 2009 Jul 30;361(5):496-509 [19641206.001]
  • [Cites] Front Immunol. 2012 Aug 23;3:256 [22936933.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2940-7 [17626838.001]
  • [Cites] J Autoimmun. 2015 Dec;65:1-18 [26515757.001]
  • (PMID = 28160012.001).
  • [ISSN] 1432-1041
  • [Journal-full-title] European journal of clinical pharmacology
  • [ISO-abbreviation] Eur. J. Clin. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Placebos; 0 / Pyridines; 0 / Quinolines; 0 / seletalisib; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Keywords] NOTNLM ; Inflammatory / PI3Kδ / Pharmacodynamic / Pharmacokinetic / Phase I / Seletalisib
  •  go-up   go-down


68. Chu CH, Davis C: Urticarial Reaction to Ustekinumab During the Treatment of Plaque Psoriasis in a Hepatitis C-Positive Patient. Drug Saf Case Rep; 2017 Dec;4(1):9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 10 months, she developed a round red rash on her skin diffusely on her body.
  • A Naranjo assessment score of 6 was obtained, indicating a probable relationship between the patient's urticaria and her use of ustekinumab.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28677075.001).
  • [ISSN] 2199-1162
  • [Journal-full-title] Drug safety - case reports
  • [ISO-abbreviation] Drug Saf Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


69. Abruzzo A, Armenise N, Bigucci F, Cerchiara T, Gösser MB, Samorì C, Galletti P, Tagliavini E, Brown DM, Johnston HJ, Fernandes TF, Luppi B: Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone. Int J Pharm; 2017 May 30;524(1-2):9-15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surfactants from itaconic acid: Toxicity to HaCaT keratinocytes in vitro, micellar solubilization, and skin permeation enhancement of hydrocortisone.
  • One of the most widely used approaches for improving drug permeation across the stratum corneum barrier of the skin is the use of chemical penetration enhancers, such as surfactants.
  • Assessment of impacts on HaCaT keratinocyte cell viability was used as indicator of their potential to cause skin irritation 24h post exposure (Alamar Blue assay).
  • The effect of different surfactant concentrations (up to ten times the critical micellar concentration, CMC) on hydrocortisone (HC) solubility and permeation through porcine skin was also evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28356226.001).
  • [ISSN] 1873-3476
  • [Journal-full-title] International journal of pharmaceutics
  • [ISO-abbreviation] Int J Pharm
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Cytotoxicity / Hydrocortisone / Keratinocyte / Micellar solubilization / Skin permeation enhancement / Surfactants
  •  go-up   go-down


70. Dentan C, Forestier E, Roustit M, Boisset S, Chanoine S, Epaulard O, Pavese P: Assessment of linezolid prescriptions in three French hospitals. Eur J Clin Microbiol Infect Dis; 2017 Jul;36(7):1133-1141

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of linezolid prescriptions in three French hospitals.
  • Linezolid is approved in pneumonia and complicated skin and soft tissue infections.
  • Educational programs are mandatory to improve practices, as well as clinical studies to better assess the efficacy and safety of linezolid in clinical situations other than pneumonia or complicated skin and soft tissue infections.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28127641.001).
  • [ISSN] 1435-4373
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Rodrigues AM, Sniehotta FF, Birch-Machin MA, Araujo-Soares V: Aware, motivated and striving for a 'safe tan': an exploratory mixed-method study of sun-protection during holidays. Health Psychol Behav Med; 2017;5(1):276-298

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • <b>Methods:</b> Seventeen participants aged 21-62 years old, recruited from community settings took part in individual face-to-face semi-structured interviews, completed sun sensitivity questions and an objective assessment of sunscreen use.
  • They are aware of the need to protect from solar UVR, but the motive for a safe tan, the overreliance on sunscreen, the overestimation of the safe sun-exposure time for their skin type and the insufficient application of sunscreen leaves holidaymakers motivated to protect their skin at significant risk of overexposure, sunburn and skin cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2016 Dec;175(6):1401-1403 [27292412.001]
  • [Cites] Int J Behav Nutr Phys Act. 2015 Feb 21;12:25 [25889481.001]
  • [Cites] Pediatrics. 2002 Jun;109(6):1009-14 [12042536.001]
  • [Cites] Health Psychol. 2000 Sep;19(5):469-78 [11007155.001]
  • [Cites] Health Educ Res. 2011 Feb;26(1):39-52 [21059798.001]
  • [Cites] J Skin Cancer. 2012;2012:480985 [22649734.001]
  • [Cites] Health Educ Behav. 2001 Jun;28(3):290-305 [11380050.001]
  • [Cites] Implement Sci. 2012 Apr 24;7:35 [22531601.001]
  • [Cites] Br J Cancer. 2011 Dec 6;105 Suppl 2:S66-9 [22158324.001]
  • [Cites] J Natl Cancer Inst. 1998 Dec 16;90(24):1873-80 [9862624.001]
  • [Cites] Eur J Public Health. 2006 Oct;16(5):492-7 [16195355.001]
  • [Cites] J Am Acad Dermatol. 2002 May;46(5):683-9 [12004307.001]
  • [Cites] Psychooncology. 2016 Feb;25(2):158-63 [26101815.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:116-23 [19775367.001]
  • [Cites] Br J Dermatol. 2009 Nov;161 Suppl 3:25-7 [19775353.001]
  • [Cites] Health Psychol. 2003 Mar;22(2):199-209 [12683740.001]
  • [Cites] Health Educ Res. 2010 Feb;25(1):162-82 [19858077.001]
  • [Cites] Arch Dermatol. 2010 Sep;146(9):979-84 [20855696.001]
  • [Cites] J Cosmet Dermatol. 2004 Apr;3(2):62-8 [17147557.001]
  • [Cites] Psychol Health. 2013;28(5):477-94 [23252669.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2015 Feb;29 Suppl 2:6-10 [25639926.001]
  • [Cites] J Behav Med. 2009 Dec;32(6):532-44 [19653089.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2583-93 [22016471.001]
  • [Cites] Health Educ J. 2009 Sep;68(3):232-243 [22707763.001]
  • [Cites] Ann Behav Med. 2013 Apr;45(2):224-38 [23229160.001]
  • [Cites] BMC Public Health. 2011 Aug 31;11:679 [21884577.001]
  • [Cites] Health Educ Behav. 2003 Feb;30(1):29-43 [12564666.001]
  • [Cites] J Clin Oncol. 2011 Jan 20;29(3):257-63 [21135266.001]
  • [Cites] Health Educ Res. 2005 Oct;20(5):579-85 [15644381.001]
  • [Cites] Psychol Health. 2010 Dec;25(10):1229-45 [20204937.001]
  • [Cites] Am J Prev Med. 2004 Dec;27(5):422-66 [15556744.001]
  • [Cites] J Psychol. 1975 Sep;91(1):93-114 [28136248.001]
  • [Cites] Arch Dermatol. 2008 Nov;144(11):1449-55 [19015419.001]
  • [Cites] Qual Saf Health Care. 2005 Feb;14 (1):26-33 [15692000.001]
  • [Cites] J Behav Med. 2013 Apr;36(2):109-23 [22460361.001]
  • [Cites] J Public Health (Oxf). 2014 Mar;36(1):56-64 [23365261.001]
  • [Cites] Int J Environ Res Public Health. 2016 Jan 19;13(1):null [26797627.001]
  • [Cites] Photochem Photobiol Sci. 2013 Jan;12(1):190-6 [23023728.001]
  • [Cites] Cancer Causes Control. 2011 Jul;22(7):1067-71 [21637987.001]
  • [Cites] Health Psychol. 1988;7(4):355-86 [3049068.001]
  • [Cites] J Invest Dermatol. 2007 Jan;127(1):41-8 [17068486.001]
  • [Cites] Pigment Cell Melanoma Res. 2010 Feb;23(1):57-63 [19968819.001]
  • [Cites] Br J Health Psychol. 2013 Feb;18(1):182-217 [22989352.001]
  • [Cites] Arch Dermatol. 1988 Jun;124(6):869-71 [3377516.001]
  • [Cites] J Behav Med. 1997 Apr;20(2):207-22 [9144041.001]
  • [Cites] BMJ Open. 2013 Jun 28;3(6):null [23811173.001]
  • [Cites] Am J Health Behav. 2004 Nov-Dec;28(6):531-41 [15569587.001]
  • (PMID = 28670503.001).
  • [ISSN] 2164-2850
  • [Journal-full-title] Health psychology and behavioral medicine
  • [ISO-abbreviation] Health Psychol Behav Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Sun-safety / interview / public health / skin cancer / tanning
  •  go-up   go-down


72. Wang S, Mi J, Li Q, Jin R, Dong J: Fractional microplasma radiofrequency technology for non-hypertrophic post-burn scars in Asians: A prospective study of 95 patients. Lasers Surg Med; 2017 Feb 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among the various techniques, fractional microplasma radiofrequency technology (FMRT) has proven to be an effective treatment option for various types of scars and skin conditions such as rhytids, striae distensae, and hyperpigmentation.
  • OBJECTIVE: This prospective clinical trial was designed to evaluate the efficacy and safety of FMRT for treating non-hypertrophic post-burn scars in the Asian population.
  • The Patient and Observer Scar Assessment Scales (POSAS) [20] were used to evaluate changes in burn scars pre-and post-FMRT treatment.
  • No severe adverse events, such as acute skin infection, hypertrophic scarring, or depigmentation, were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28220505.001).
  • [ISSN] 1096-9101
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; burns / cicatrix / lasers / micro-plasma / radiofrequency / scars
  •  go-up   go-down


73. Hojerová J, Peráčková Z, Beránková M: Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication. Food Chem Toxicol; 2017 May;103:66-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Margin of safety for two UV filters estimated by in vitro permeation studies mimicking consumer habits: Effects of skin shaving and sunscreen reapplication.
  • Sunscreens are intended to work on the skin.
  • The potential for systemic absorption of Benzophenone-3 (BP3, 10%) and Ethylhexyl Triazone (EHT, 5%) in a silicone-based water-in-oil emulsion was assessed in vitro using a full-thickness porcine-ear skin mimicking in-use conditions.
  • (ii) on the whole-body skin, was (i) 136 and 30;.
  • Skin shaving increased BP3 and EHT bioavailability 1.38 and 1.80-fold, respectively.
  • Margin of Safety values were estimated according to guidelines applicable for European Union.
  • For three realistic exposure scenarios, MoS of 48, 34 and 34 for BP3 in the sunscreen applied on the whole-body indicate some concerns regarding the safety for consumers (MoS<100).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28216167.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Benzophenone-3 / Ethylhexyl triazone / Human exposure assessment / Margin of safety / Shaving skin / Systemic exposure dose
  •  go-up   go-down


74. Jones K, Johnson PD, Baldwin PEJ, Coldwell M, Cooke J, Keen C, Harding AH, Smith D, Cocker J: Exposure to Diisocyanates and Their Corresponding Diamines in Seven Different Workplaces. Ann Work Expo Health; 2017 Apr 01;61(3):383-393

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of this, any exposure to the diamines themselves released during the industrial process could confound the assessment of diisocyanate exposure.
  • This paper reports an initial assessment of the extent of diamine formation and exposure during different processes involving diisocyanates including casting, grouting, core making, spray painting, foam blowing, and floor screeding.
  • Some non-aerosol processes gave rise to substantial diamine levels in urine (in exceedance of international guidance values, >5 µmol mol-1 creatinine) despite airborne levels being well within occupational exposure limits (20 µg m-3 total NCO in Great Britain); measurement data and statistical modelling indicated that skin absorption was the most likely exposure route.
  • It also demonstrates the potential for substantial skin absorption of diisocyanates in certain processes such as floor screeding and foam production.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Crown Copyright 2017.
  • (PMID = 28355438.001).
  • [ISSN] 2398-7316
  • [Journal-full-title] Annals of work exposures and health
  • [ISO-abbreviation] Ann Work Expo Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; NCO / diamines / diisocyanates / floor screeding / foam blowing / skin absorption
  •  go-up   go-down


75. Kendall R, Lenoir J, Gerrard S, Scheuerle RL, Slater NK, Tuleu C: Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System. Pharm Res; 2017 Feb 13;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using the Slug Mucosal Irritation Assay to Investigate the Tolerability of Tablet Excipients on Human Skin in the Context of the Use of a Nipple Shield Delivery System.
  • However concerns exist around dermatological nipple tolerability with no pharmaceutical safety assessment guidance to study local tissue tolerance of the nipple and the areola.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28194635.001).
  • [ISSN] 1573-904X
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; nipple shield delivery system / pediatric / skin tolerability / slug mucosal irritation assay / tablet excipients
  •  go-up   go-down


76. Cameli N, Mariano M, Cordone I, Abril E, Masi S, Foddai ML: Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment. Dermatol Surg; 2017 Jun;43(6):826-835
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment.
  • BACKGROUND: Platelet-rich plasma (PRP) is an emerging treatment in dermatology recently proposed for skin rejuvenation.
  • OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.
  • RESULTS: Clinical and patient evaluation showed improvement of skin texture.
  • Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved.
  • CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28375975.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Greveling K, Prens EP, Liu L, van Doorn MB: Non-invasive anaesthetic methods for dermatological laser procedures: a systematic review. J Eur Acad Dermatol Venereol; 2017 Jan 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this systematic review was therefore to assess the efficacy and safety of non-invasive anaesthetic methods during dermatological laser procedures.
  • The quality of evidence was rated using Grading of Recommendations Assessment, Development and Evaluation (GRADE).
  • The non-invasive anaesthetic methods (i.e. topical anaesthetic drugs, skin cooling, and pneumatic skin flattening [PSF]), types of lasers, laser settings, application time, and types of pain scales varied widely among the included studies.
  • In general, active non-invasive anaesthetic methods seemed to provide favourable results compared to placebo or no anaesthesia, and topical anaesthetic drugs and PSF seemed to result in a better pain reduction than skin cooling.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 European Academy of Dermatology and Venereology.
  • (PMID = 28107576.001).
  • [ISSN] 1468-3083
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


78. Sowada J, Lemoine L, Schön K, Hutzler C, Luch A, Tralau T: Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin. Arch Toxicol; 2017 Jun;91(6):2331-2341

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxification of polycyclic aromatic hydrocarbons by commensal bacteria from human skin.
  • This study now shows that readily isolable skin commensals transform B[a]P into a range of highly cyto- and genotoxic metabolites that are excreted in toxicologically relevant concentrations during growth.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2005 Jul 11;33(12):3799-811 [16009812.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):492-7 [19414215.001]
  • [Cites] Arch Toxicol. 2016 Jun;90(6):1449-58 [26238291.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):113-25 [15660110.001]
  • [Cites] Atmos Environ. 1969 Sep;3(5):565-72 [4187590.001]
  • [Cites] Science. 2009 Dec 18;326(5960):1694-7 [19892944.001]
  • [Cites] Appl Microbiol Biotechnol. 2006 Jul;71(4):522-32 [16317545.001]
  • [Cites] Environ Mol Mutagen. 2005 Mar-Apr;45(2-3):106-14 [15688365.001]
  • [Cites] EXS. 2009;99:151-79 [19157061.001]
  • [Cites] MBio. 2013 Oct 29;4(6):e00782-13 [24169577.001]
  • [Cites] Arch Toxicol. 2014 Dec;88(12):2135-90 [25370008.001]
  • [Cites] Environ Toxicol Chem. 2001 Mar;20(3):632-43 [11349866.001]
  • [Cites] FEMS Microbiol Lett. 2003 Jun 27;223(2):177-83 [12829283.001]
  • [Cites] Methods Enzymol. 1990;188:148-53 [2280701.001]
  • [Cites] J Hazard Mater. 2009 Sep 30;169(1-3):1-15 [19442441.001]
  • [Cites] Chem Res Toxicol. 2011 Oct 17;24(10 ):1653-67 [21916506.001]
  • [Cites] Environ Sci Pollut Res Int. 2015 Nov;22(21):16393-404 [25471715.001]
  • [Cites] FEMS Microbiol Ecol. 2014 Apr;88(1):129-39 [24372170.001]
  • [Cites] Crit Rev Microbiol. 2015;41(3):326-40 [24645635.001]
  • [Cites] Cell Mol Life Sci. 2015 Apr;72(8):1499-515 [25548803.001]
  • [Cites] Cell. 2016 May 5;165(4):801-11 [27153494.001]
  • [Cites] Science. 2009 May 29;324(5931):1190-2 [19478181.001]
  • [Cites] J Environ Monit. 2007 Sep;9(9):1001-8 [17726562.001]
  • [Cites] Toxicol Lett. 2013 Apr 12;218(2):97-104 [23391484.001]
  • [Cites] EXS. 2009;99:57-86 [19157058.001]
  • [Cites] Carcinogenesis. 1998 Oct;19(10):1847-53 [9806168.001]
  • [Cites] Environ Monit Assess. 2008 Apr;139(1-3):107-18 [17566864.001]
  • [Cites] Biomed Chromatogr. 2016 Mar;30(3):474-83 [26230188.001]
  • [Cites] PLoS One. 2016 Jan 15;11(1):e0147239 [26771904.001]
  • [Cites] Cell. 2012 Mar 16;148(6):1258-70 [22424233.001]
  • [Cites] Drug Metab Pharmacokinet. 2006 Aug;21(4):257-76 [16946553.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):411-25 [25476418.001]
  • [Cites] Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42 [7703357.001]
  • [Cites] FEMS Microbiol Rev. 2008 Nov;32(6):927-55 [18662317.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):908-15 [10706104.001]
  • [Cites] Mucosal Immunol. 2012 Sep;5(5):567-79 [22617837.001]
  • [Cites] Exp Dermatol. 2012 May;21(5):364-9 [22509834.001]
  • [Cites] Curr Opin Chem Biol. 2013 Jun;17(3):379-84 [23680493.001]
  • [Cites] Environ Mol Mutagen. 2016 Apr;57(3):229-35 [26919089.001]
  • [Cites] Biochemistry. 1977 Apr 5;16(7):1467-73 [191070.001]
  • [Cites] Toxicol Sci. 2013 Feb;131(2):351-9 [23148024.001]
  • (PMID = 28378121.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Keywords] NOTNLM ; Benzo[a]pyrene / Cytotoxicity / Genotoxicity / Microbiome / PAHs / Polycyclic aromatic hydrocarbons / Toxification
  •  go-up   go-down


79. Capogrosso P, Ventimiglia E, Oreggia D, Salonia A, Montorsi F: Medical treatment of erectile dysfunction: too many medical prescriptions? Urologia; 2017 Jul 05;:0

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Being user-friendly compounds with an excellent overall safety profile, PDE5is emerged as the first-line treatment for ED, thus overcoming topical alprostadil and intracavernous injections (ICIs).
  • Thereof, a careful assessment of the so-called modifiable and reversible ED risk factors along with a patient-tailored screening for potential contraindications to the treatment itself should be performed in every case.
  • Lastly, although conclusive data still lack, the potential association between life-risky PDE5is side effects (i.e. cardiovascular adverse events, melanoma skin cancer and worsening of prostate cancer outcomes) should be carefully taken into account when counselling patients for ED treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28708203.001).
  • [ISSN] 0391-5603
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


80. Waldmann V, Narayanan K, Combes N, Jost D, Jouven X, Marijon E: Electrical cardiac injuries: current concepts and management. Eur Heart J; 2017 Apr 20;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Electrical injuries can range from minor skin burns to life threatening internal organ damage.
  • A thorough clinical assessment to ascertain the path of current through the body and possible internal injury is essential.
  • Public education and increasing workplace as well as home safety measures are key steps in prevention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28444167.001).
  • [ISSN] 1522-9645
  • [Journal-full-title] European heart journal
  • [ISO-abbreviation] Eur. Heart J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Cardiac arrhythmias / Electric injuries / Lightning / Management / Physiopathology
  •  go-up   go-down


81. Jiang Y, Zhang X, Lu Z, Gold MH: Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity. J Cosmet Laser Ther; 2016 Dec 21;:1-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of efficacy and safety of a fractionated bipolar radiofrequency device for the treatment of lower face wrinkles and laxity.
  • : Skin aging, as a natural course, is a gradual process.
  • Fractional bipolar RF as a novel means of rejuvenation has been used in clinical practice, but questions remain in terms of its efficacy and safety.
  • Considering a large population in our country and huge demands for skin tightening, we did this research to evaluate the efficacy and safety of fractional bipolar radiofrequency.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001455.001).
  • [ISSN] 1476-4180
  • [Journal-full-title] Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology
  • [ISO-abbreviation] J Cosmet Laser Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; MFWS / bipolar fractionated radiofrequency / skin laxity / wrinkle treatment
  •  go-up   go-down


82. Narita K, Vo PTH, Yamamoto K, Kojima H, Itagaki H: Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays. Toxicol In Vitro; 2017 Aug;42:69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventing false-negatives in the in vitro skin sensitization testing of acid anhydrides using interleukin-8 release assays.
  • In vitro safety tests may be used as replacements for animal tests owing to their accuracy and high-throughput performance.
  • However, several in vitro skin sensitization tests produce false-negative results such as acid anhydride.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28411127.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alternative / Drug exposure / False-negative / In vitro / Skin sensitization test / THP-1 cells
  •  go-up   go-down


83. Considine J, Hutchison AF, Rawson H, Hutchinson AM, Bucknall T, Dunning T, Botti M, Duke MM, Street M: Comparison of policies for recognising and responding to clinical deterioration across five Victorian health services. Aust Health Rev; 2017 May 25;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most health services' definitions of physiological observations fulfilled national standards in terms of minimum parameters and frequency of assessment.
  • </b> Recognising and responding to clinical deterioration is a major patient safety priority.
  • Although nurses are largely responsible for physiological observations and escalation of care, they have little authority to direct frequency of observations and triggers for care escalation or tailor assessment to individual patient needs.
  • </b> Inconsistencies in recommendations regarding physiological observations and escalation of care criteria may create patient safety issues when students and staff work across organisations or move from one organisation to another.
  • The validity of other parameters, such as appearance, pain, skin colour and cognition, warrant further consideration as early indicators of deterioration that may be used by nurses to identify clinical deterioration earlier.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28538140.001).
  • [ISSN] 0156-5788
  • [Journal-full-title] Australian health review : a publication of the Australian Hospital Association
  • [ISO-abbreviation] Aust Health Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Fichtenbaum EJ, Strine AC, Concodora CW, Schulte M, Noh PH: Tubeless outpatient robotic upper urinary tract reconstruction in the pediatric population: short-term assessment of safety. J Robot Surg; 2017 Jun 21;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubeless outpatient robotic upper urinary tract reconstruction in the pediatric population: short-term assessment of safety.
  • The aim of the study was to assess the safety of performing tubeless robotic UUTR as an outpatient procedure.
  • Median operative time was 167 min (range 108-249), defined as skin incision to closure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28639117.001).
  • [ISSN] 1863-2491
  • [Journal-full-title] Journal of robotic surgery
  • [ISO-abbreviation] J Robot Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Ambulatory surgical procedures / Pediatrics / Surgical procedures, robotic / Ureteral obstruction
  •  go-up   go-down


85. McKanna M, Geraci J, Hall K, Hauan B, Howell M, Huey T, Lucius A, Mendez-Eastman S, Purcell K, Raizman R, Shepherd D, Gabriel A: Clinician Panel Recommendations for Use of Negative Pressure Wound Therapy with Instillation. Ostomy Wound Manage; 2016 Apr;62(4):S1-S14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Panelists agreed NPWTi-d is primarily suited to prepare surgical or nonsurgical wounds for delayed primary closure and preparing/protecting periwound skin improves maintenance of a tight seal.
  • Panelists also emphasized the im- portance of wound assessment and documentation and recommend educating the patient, family members, and other members of the patient-care team.
  • Research to compare the safety, ef cacy, and effectiveness of NPWTi-d and other irrigation techniques on patient outcomes and research to validate these recommendations is needed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28657895.001).
  • [ISSN] 1943-2720
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Guo Y, Gu Z, Liu X, Liu J, Ma M, Chen B, Wang L: Rapid Analysis of Corni fructus Using Paper Spray-Mass Spectrometry. Phytochem Anal; 2017 Jul;28(4):344-350

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a number of counterfeits of Corni fructus, such as Crataegi fructus, Lycii fructus, and grape skin are illegally sold in crude herb markets.
  • Therefore, the development of a rapid and high-throughput quality evaluation method is important for ensuring the effectiveness and safety of the crude materials of Corni fructus.
  • OBJECTIVE: To develop PS-MS chemical profiles and a semi-quantitative method of Corni fructus for quality assessment and control, and species distinction of Corni fructus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 John Wiley & Sons, Ltd.
  • (PMID = 28239915.001).
  • [ISSN] 1099-1565
  • [Journal-full-title] Phytochemical analysis : PCA
  • [ISO-abbreviation] Phytochem Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Corni fructus / chemical profile / paper spray-mass spectrometry / rapid analysis / species distinction
  •  go-up   go-down


87. Xiong J, Chiu Y, Pradhan RS, Li X, Li X, Carlson DM, Awni W: Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer. J Clin Oncol; 2011 May 20;29(15_suppl):e13082

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.
  • The aim of this assessment was to evaluate the impact of ethnicity on linifanib tolerability and pharmacokinetics (PK) in cancer patients.
  • The impact of ethnicity on tolerability was assessed by evaluating significance of ethnicity on the exposure-safety relationship.
  • Logistic regression analysis was conducted to construct the exposure-safety relationship for eight common adverse events (hypertension, asthenia, GI-abdominal disorder, diarrhea, skin toxicity 1, skin toxicity 2, proteinuria and anorexia).
  • RESULTS: The exposure-safety response analysis showed that ethnicity was not a significant factor influencing the exposure-safety response relationship for any of the tested adverse events.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28019935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Wang CC, Lin YC, Wang SS, Shih C, Lin YH, Tung CW: SkinSensDB: a curated database for skin sensitization assays. J Cheminform; 2017;9:5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SkinSensDB: a curated database for skin sensitization assays.
  • Skin sensitization is an important toxicological endpoint for chemical hazard determination and safety assessment.
  • Prediction of chemical skin sensitizer had traditionally relied on data from rodent models.
  • The development of the adverse outcome pathway (AOP) and associated alternative in vitro assays have reshaped the assessment of skin sensitizers.
  • Current computational models to predict skin sensitization mainly based on in vivo assays without incorporating alternative in vitro assays.
  • However, there are few freely available databases integrating both the in vivo and the in vitro skin sensitization assays for development of AOP-based skin sensitization prediction models.
  • To facilitate the development of AOP-based prediction models, a skin sensitization database named SkinSensDB has been constructed by curating data from published AOP-related assays.
  • In addition to providing datasets for developing computational models, SkinSensDB is equipped with browsing and search tools which enable the assessment of new compounds for their skin sensitization potentials based on data from structurally similar compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS One. 2016 Jun 07;11(6):e0155419 [27271321.001]
  • [Cites] Toxicol Sci. 2004 Oct;81(2):332-43 [15254333.001]
  • [Cites] Toxicol Sci. 2008 Mar;102(1):110-9 [17932397.001]
  • [Cites] Toxicol In Vitro. 2006 Aug;20(5):774-84 [16337770.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):529-45 [24928565.001]
  • [Cites] Int J Mol Sci. 2009 Jul 17;10(7):3237-54 [19742136.001]
  • [Cites] J Cheminform. 2013 May 21;5:24 [23694746.001]
  • [Cites] Toxicology. 1995 Nov 20;103(1):63-73 [8525491.001]
  • [Cites] J Comput Chem. 2011 May;32(7):1466-74 [21425294.001]
  • [Cites] ALTEX. 2014;31(3):336-40 [24687303.001]
  • [Cites] Anal Chim Acta. 2006 Jul 21;572(2):272-82 [17723489.001]
  • [Cites] J Chem Inf Model. 2005 Jul-Aug;45(4):952-64 [16045289.001]
  • [Cites] J Appl Toxicol. 2016 Sep;36(9):1150-62 [26851134.001]
  • [Cites] Cell Mol Life Sci. 2012 Mar;69(5):763-81 [21997384.001]
  • [Cites] Chem Res Toxicol. 2007 Jan;20(1):114-28 [17226934.001]
  • [Cites] Regul Toxicol Pharmacol. 2014 Aug;69(3):371-9 [24813372.001]
  • [Cites] Food Chem Toxicol. 1992 Jan;30(1):65-9 [1544608.001]
  • [Cites] Crit Rev Toxicol. 2010 May;40(5):389-404 [20180632.001]
  • [Cites] Toxicol In Vitro. 2009 Apr;23(3):454-65 [19162165.001]
  • [Cites] Arch Toxicol. 2012 Aug;86(8):1273-95 [22707154.001]
  • [Cites] SAR QSAR Environ Res. 2013;24(12):1009-23 [23988224.001]
  • [Cites] Hum Exp Toxicol. 2015 Dec;34(12):1222-30 [26614809.001]
  • [Cites] Chem Res Toxicol. 2008 Jan;21(1):53-69 [18052130.001]
  • [Cites] Toxicol Appl Pharmacol. 2010 Jun 15;245(3):281-90 [20307559.001]
  • [Cites] Toxicol Appl Pharmacol. 2015 Apr 15;284(2):262-72 [25560674.001]
  • [Cites] Regul Toxicol Pharmacol. 2012 Aug;63(3):489-504 [22659254.001]
  • [Cites] Toxicol In Vitro. 2002 Dec;16(6):711-6 [12423654.001]
  • [Cites] Toxicol Sci. 2007 Oct;99(2):532-44 [17675333.001]
  • [Cites] J Comput Aided Mol Des. 2008 Jun-Jul;22(6-7):345-66 [18338230.001]
  • [Cites] Toxicol Sci. 2009 Nov;112(1):164-74 [19748994.001]
  • [Cites] Nucleic Acids Res. 2015 Jul 1;43(W1):W605-11 [25934803.001]
  • [Cites] Chem Res Toxicol. 2015 Oct 19;28(10):1975-86 [26382665.001]
  • (PMID = 28194231.001).
  • [Journal-full-title] Journal of cheminformatics
  • [ISO-abbreviation] J Cheminform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Al Jarallah M, Kassir R, El-Barbari M, Ali S, Debs T, Chouillard E: Three-Year Follow-Up of Laparoscopic Reduced Port Sleeve Gastrectomy in 808 Consecutive Patients. Obes Surg; 2017 May 04;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary and safety profile of <sub>R</sub>LSG as well as 3 years weight loss outcome are hereby discussed.
  • The <sub>R</sub>LSG procedure was performed using only two skin incisions.
  • Moreover, 3-year follow-up assessment confirmed adequate % EWL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28474321.001).
  • [ISSN] 1708-0428
  • [Journal-full-title] Obesity surgery
  • [ISO-abbreviation] Obes Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Gastrectomy / Laparoscopy / Obesity / Sleeve / Surgery
  •  go-up   go-down


90. Woodley DT, Cogan J, Hou Y, Lyu C, Marinkovich MP, Keene D, Chen M: Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients. J Clin Invest; 2017 Jul 10;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A double-blind, placebo-controlled pilot trial assessed safety and efficacy of topical and intradermal gentamicin in 5 RDEB patients with nonsense mutations.
  • The intradermal arm tested daily intradermal injection of gentamicin solution (8 mg) or placebo into 2 intact skin sites for 2 days in 4 of 5 patients.
  • Primary outcomes were induction of type VII collagen and AFs at the test sites and safety assessment.
  • Newly created type VII collagen varied from 20% to 165% of that expressed in normal human skin and persisted for 3 months.
  • Type VII collagen induction did not generate anti-type VII collagen autoantibodies in patients' blood or skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28691931.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Ford KA: Refinement, Reduction, and Replacement of Animal Toxicity Tests by Computational Methods. ILAR J; 2016 Dec;57(2):226-233
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Along with the potential capacity to reduce or replace the use of animals for the assessment of particular toxicological endpoints, computational models offer several advantages compared to in vitro and in vivo approaches, including cost-effectiveness, rapid availability of results, and the ability to fully standardize procedures.
  • Models are currently available to aid in the prediction of several important toxicological endpoints, including mutagenicity, carcinogenicity, eye irritation, hepatotoxicity, and skin sensitization, albeit with varying degrees of success.
  • This review serves to introduce the concepts of computational toxicology and evaluate their role in the safety assessment of compounds, while also highlighting the application of in silico methods in the support of the goal and vision of the 3Rs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research.All rights reserved. For permissions, please email: journals.permissions@oup.com.
  • (PMID = 28053075.001).
  • [ISSN] 1930-6180
  • [Journal-full-title] ILAR journal
  • [ISO-abbreviation] ILAR J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; 3Rs / QSAR / alternative testing method / computational toxicology / drug development / in silico prediction
  •  go-up   go-down


92. Vukmanović S, Sadrieh N: Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening. Crit Rev Toxicol; 2017 May;47(5):415-432

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening.
  • The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28326907.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Allergic contact dermatitis / HLA / T cells / cosmetics / delayed-type hypersensitivity / dendritic cells / fragrance / hapten / human-repeated insult patch test / keratinocytes / local lymph node assay / skin sensitization
  •  go-up   go-down


93. Agarwala SS, Thompson J, Smithers M, Ross M, Coventry B, Minor D, Scoggins C, Hersey P, Wachter E: Chemoablation of melanoma with intralesional rose bengal (PV-10). J Clin Oncol; 2009 May 20;27(15_suppl):9060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An additional 1-2 lesions, including visceral lesions, remain untreated for assessment of bystander response.
  • A modified Fleming design allows interim assessment of safety and OR at weeks 4 and 24, respectively, after treatment of the 20<sup>th</sup> and 40<sup>th</sup> subjects.
  • RESULTS: Interim safety data for the first 40 subjects treated is comparable to phase 1, with transient mild to moderate locoregional pain, vesicles or edema most common; Grade 3 AEs have been rare (1 case each of vesicles and skin flap necrosis), with no Grade 4 or 5 AEs attributed to PV-10.
  • CONCLUSIONS: The safety and efficacy profile of intralesional therapy with PV-10 compares favorably with available therapeutic options for this patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962145.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Thomas KS, Bradshaw LE, Sach TH, Cowdell F, Batchelor JM, Lawton S, Harrison EF, Haines RH, Ahmed A, Dean T, Burrows NP, Pollock I, Buckley HK, Williams HC, Llewellyn J, Crang C, Grundy JD, Guiness J, Gribbin A, Wake EV, Mitchell EJ, Brown SJ, Montgomery AA: Randomised controlled trial of silk therapeutic garments for the management of atopic eczema in children: the CLOTHES trial. Health Technol Assess; 2017 Apr;21(16):1-260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Atopic eczema (AE) is a chronic, itchy, inflammatory skin condition that affects the quality of life of children and their families.
  • Secondary outcomes - patient-reported eczema symptoms (Patient Oriented Eczema Measure); global assessment of severity (Investigator Global Assessment); quality of life of the child (Atopic Dermatitis Quality of Life, Child Health Utility - 9 Dimensions), family (Dermatitis Family Impact Questionnaire) and main carer (EuroQoL-5 Dimensions-3 Levels); use of standard eczema treatments (e.g. emollients, topical corticosteroids); and cost-effectiveness.
  • Safety outcomes - number of skin infections and hospitalisations for AE.
  • Skin infections occurred in 39 out of 141 (28%) and 36 out of 142 (25%) participants for standard care and silk clothing groups, respectively.
  • FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in <i>Health Technology Assessment</i>; Vol.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28409557.001).
  • [ISSN] 2046-4924
  • [Journal-full-title] Health technology assessment (Winchester, England)
  • [ISO-abbreviation] Health Technol Assess
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Api AM, Belsito D, Botelho D, Browne D, Bruze M, Burton GA Jr, Buschmann J, Calow P, Dagli ML, Date M, Dekant W, Deodhar C, Fryer AD, Joshi K, La Cava S, Lapczynski A, Liebler DC, O'Brien D, Parakhia R, Patel A, Penning TM, Ritacco G, Romine J, Salvito D, Schultz TW, Sipes IG, Thakkar Y, Tsang S, Wahler J: RIFM fragrance ingredient safety assessment, acetic acid, C7-9-branched alkyl esters, C8-rich, CAS Registry Number 108419-32-5. Food Chem Toxicol; 2017 May 30;
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RIFM fragrance ingredient safety assessment, acetic acid, C7-9-branched alkyl esters, C8-rich, CAS Registry Number 108419-32-5.
  • This material was evaluated for genotoxicity, repeated dose toxicity, developmental and reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, as well as environmental safety.
  • Data from the suitable read across analog isoamyl acetate (CAS# 123-92-2) show that this material does not have skin sensitization potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28576467.001).
  • [ISSN] 1873-6351
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Developmental and reproductive toxicity / Environmental safety / Genotoxicity / Local respiratory toxicity / Phototoxicity/photoallergenicity / Repeated dose / Skin sensitization
  •  go-up   go-down


96. Galimberti V, Vicini E, Corso G, Morigi C, Fontana S, Sacchini V, Veronesi P: Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications. Breast; 2017 Jun 30;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple-sparing and skin-sparing mastectomy: Review of aims, oncological safety and contraindications.
  • Skin-sparing (SSM) and nipple-sparing (NSM) mastectomies are relatively new conservative surgical approaches to breast cancer.
  • In SSM most of the breast skin is conserved to create a pocket that facilitates immediate breast reconstruction with implant or autologous graft to achieve a quality cosmetic outcome.
  • Tumor not less than 2 cm from the NAC is recommended, but may be less important than no evidence of nipple involvement on mandatory intraoperative nipple margin assessment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier Ltd. All rights reserved.
  • (PMID = 28673535.001).
  • [ISSN] 1532-3080
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Breast cancer / Conservative mastectomy / NSM / Oncoplastic surgery / Skin-sparing mastectomy
  •  go-up   go-down


97. White MC, Peterschmidt J, Callahan J, Fitzgerald JE, Close KL: Interval follow up of a 4-day pilot program to implement the WHO surgical safety checklist at a Congolese hospital. Global Health; 2017 Jun 29;13(1):42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interval follow up of a 4-day pilot program to implement the WHO surgical safety checklist at a Congolese hospital.
  • BACKGROUND: The World Health Organisation Surgical Safety Checklist (SSC) improves surgical outcomes and the research question is no longer 'does the SSC work?
  • Over half the participants were following the six processes measures always or most of the time: confirmation of patient identity and the surgical procedure (57%), assessment of difficult intubation risk (72%), assessment of the risk of major blood loss (86%), antibiotic prophylaxis given before skin incision (86%), use of a pulse oximeter (86%), and counting sponges and instruments (71%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Patient Saf Surg. 2014 Mar 28;8:16 [24678854.001]
  • [Cites] BMJ Open. 2013 Aug 15;3(8):e003039 [23950205.001]
  • [Cites] Br J Surg. 2016 Jul;103(8):971-88 [27145169.001]
  • [Cites] Ann Surg. 2013 Apr;257(4):633-9 [23207242.001]
  • [Cites] J Am Coll Surg. 2011 May;212(5):873-9 [21398154.001]
  • [Cites] Ann Surg. 2012 Jan;255(1):44-9 [22123159.001]
  • [Cites] Br J Surg. 2014 Feb;101(3):150-8 [24469615.001]
  • [Cites] Ann Surg. 2016 Jan;263(1):58-63 [25775063.001]
  • [Cites] Anaesthesia. 2015 Dec;70(12):1345-55 [26558855.001]
  • [Cites] Jt Comm J Qual Patient Saf. 2012 Jun;38(6):254-60 [22737776.001]
  • [Cites] Am J Surg. 2014 Jul;208(1):65-72 [24524864.001]
  • [Cites] Surg Infect (Larchmt). 2012 Feb;13(1):50-6 [22390354.001]
  • [Cites] BMJ Qual Saf. 2015 Dec;24(12 ):776-86 [26199428.001]
  • [Cites] Ann Surg. 2015 May;261(5):821-8 [24824415.001]
  • [Cites] N Engl J Med. 2009 Jan 29;360(5):491-9 [19144931.001]
  • [Cites] Ann Surg. 2013 Dec;258(6):856-71 [24169160.001]
  • (PMID = 28662709.001).
  • [ISSN] 1744-8603
  • [Journal-full-title] Globalization and health
  • [ISO-abbreviation] Global Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Checklist / Education / Global surgery / Patient safety
  •  go-up   go-down


98. Gawdat HI, Tawdy AM, Hegazy RA, Zakaria MM, Allam RS: Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study. J Cosmet Dermatol; 2017 Apr 05;
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous platelet-rich plasma versus readymade growth factors in skin rejuvenation: A split face study.
  • BACKGROUND: The escalating urge for a youthful-looking skin instigates continuous innovations with minimally invasive procedures.
  • OBJECTIVE: Compare the efficacy and safety of PRP to readymade growth factors in skin rejuvenation.
  • PATIENTS AND METHODS: Twenty adult females with Fitzpatrick skin types III-IV and Glogau photoaging types II and III were enrolled in this study.
  • RESULTS: Both procedures yielded significant improvement regarding both GAIS (skin turgor and overall vitality) and OCT (epidermal and dermal thickness) assessment.
  • CONCLUSION: Platelet-rich plasma is effective and safe for skin rejuvenation, comparable to readymade growth factors with noticeable higher longevity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2017 Wiley Periodicals, Inc.
  • (PMID = 28382785.001).
  • [ISSN] 1473-2165
  • [Journal-full-title] Journal of cosmetic dermatology
  • [ISO-abbreviation] J Cosmet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; OCT / PRP / efficacy / readymade growth factors / skin rejuvenation
  •  go-up   go-down


99. Terao T, Ishida A, Kimura T, Yoshida M, Hara T: Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report. Neuropsychiatr Dis Treat; 2017;13:1441-1448

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of safety and efficacy of lamotrigine over the course of 1-year observation in Japanese patients with bipolar disorder: post-marketing surveillance study report.
  • BACKGROUND: A post-marketing surveillance (PMS) study was conducted with a 1-year observation period to assess the safety and efficacy of lamotrigine in routine clinical practice in patients with bipolar disorder (BD).
  • Skin disorders occurred in 130 patients (13.1%), mostly within 8 weeks post treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmacoepidemiol Drug Saf. 2010 May;19(5):518-24 [20235081.001]
  • [Cites] Arch Gen Psychiatry. 2003 Mar;60(3):261-9 [12622659.001]
  • [Cites] Eur Neuropsychopharmacol. 2012 May;22(5):339-46 [22000157.001]
  • [Cites] J Clin Psychiatry. 2002 Feb;63(2):120-5 [11874212.001]
  • [Cites] Neuropsychiatr Dis Treat. 2016 Aug 31;12:2265-71 [27621637.001]
  • [Cites] Drug Saf. 1998 Apr;18(4):281-96 [9565739.001]
  • [Cites] Arch Gen Psychiatry. 2002 Jun;59(6):530-7 [12044195.001]
  • [Cites] CNS Spectr. 2006 Jun;11(6):465-71 [16816785.001]
  • [Cites] J Clin Psychiatry. 2003 Sep;64(9):1013-24 [14628976.001]
  • [Cites] Arch Gen Psychiatry. 2003 Apr;60(4):392-400 [12695317.001]
  • [Cites] Psychiatr Q. 2012 Sep;83(3):371-83 [22322995.001]
  • (PMID = 28652744.001).
  • [ISSN] 1176-6328
  • [Journal-full-title] Neuropsychiatric disease and treatment
  • [ISO-abbreviation] Neuropsychiatr Dis Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; bipolar / efficacy / lamotrigine / mood episode / post-marketing surveillance study / safety
  •  go-up   go-down


100. Luton A, Hernandez J, Patterson CR, Nielsen-Farrell J, Thompson A, Kaiser JR: Preventing Pressure Injuries in Neonates Undergoing Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: An Interprofessional Quality Improvement Project. Adv Neonatal Care; 2017 Jan 30;

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Interventions centered on revision of current protocols, with efforts to optimize product selection, hardwire assessment practices, and refine documentation of patient care and outcomes.
  • IMPLICATIONS FOR PRACTICE: Recognizing the unique skin protection needs of special populations within the NICU, such as those undergoing TH, is crucial.
  • IMPLICATIONS FOR RESEARCH: A paucity of literature regarding the unique skin protection needs for babies undergoing TH exists.
  • Work should be done to better describe the influence of TH on skin integrity, with the goal of identifying population-specific protective measures.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28141600.001).
  • [ISSN] 1536-0911
  • [Journal-full-title] Advances in neonatal care : official journal of the National Association of Neonatal Nurses
  • [ISO-abbreviation] Adv Neonatal Care
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement